Patent Application
20230075211
This application claims priority to Japanese Patent Application Nos. 2020-136804, filed on Aug. 13, 2020 and No. 2021-055622, filed on Mar. 29, 2021, in the Japanese Patent Office and Korean Patent Application No. 10-2021-0089141, filed on Jul. 7, 2021, in the Korean Intellectual Property Office, the contents of which are incorporated herein in their entireties by reference.
The present disclosure relates to condensed cyclic compounds, organic light-emitting devices including the condensed cyclic compounds, and electronic apparatuses including the organic light-emitting devices.
Organic light-emitting devices are self-emission devices that have wide viewing angles, high contrast ratios, and short response times, exhibit excellent characteristics in terms of luminance, driving voltage, and response speed, and produce full-color images.
In an example, an organic light-emitting device includes an anode, a cathode, and an organic layer that is arranged between the anode and the cathode and includes an emission layer. A hole transport region may be arranged between the anode and the emission layer, and an electron transport region may be arranged between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. Carriers, such as holes and electrons, recombine in the emission layer to produce excitons. These excitons transition from an excited state to a ground state to thereby generate light.
Provided are condensed cyclic compounds, organic light-emitting devices including the condensed cyclic compounds, and electronic apparatuses including the organic light-emitting devices.
Additional aspects will be set forth in part in the description, which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments of the disclosure.
According to an aspect of an embodiment, provided is a condensed cyclic compound represented by Formula 1-1 or 1-2:
wherein, in Formulae 1-1 and 1-2,
CY1 to CY3 are each independently a C5-C60 carbocyclic group or a C1-C60 heterocyclic group,
at least one of CY1 and CY2 is a group represented by Formula 2-1 or 2-2,
X1 is O, S, Se, Te, N(R1a), or C(R1a)(R1b),
X2 is O, S, Se, Te, N(R2a), or C(R2a)(R2b),
Y1 is O, S, Se, Te, N(R3a), or C(R3a)(R3b),
Z1 is B, Al, Si(R4a), Ge(R4a), P, P(═O), or P(═S),
R1 to R3, R1a to R4a, and R1b to R3b are each independently hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),
R1 to R3, R1a to R4a, and R1b to R3b are optionally linked to each other or via a single bond to form a C8-C60 polycyclic group that is unsubstituted or substituted with at least one R10a,
d1 to d3 are each independently an integer from 0 to 20,
in Formulae 2-1 and 2-2,
CY11 and CY12 are each independently a C5-C60 carbocyclic group, a C1-C60 heterocyclic group, or a group represented by Formula 3,
CY13 is condensed with CY1, CY2, or each of CY1 and CY2, one of the bonds marked with a dotted line in CY13 indicates a binding site to a bond marked with a solid line in CY1 or CY2,
in Formula 3,
CY4 to CY6 are each independently a C5-C60 carbocyclic group or a C1-C60 heterocyclic group,
X4 is O, S, Se, Te, N(R5a), or C(R5a)(R5b),
X5 is O, S, Se, Te, N(R6a), or C(R6a)(R6b),
Z2 is B, Al, Si(R7a), Ge(R7a), P, P(═O), or P(═S),
R5a to R7a, R5b, and R6b are each independently the same as described in connection with R1a,
R10a is:
deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group;
a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q11)(Q12)(Q13), —N(Q11)(Q12), —B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof;
a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, or a C6-C60 arylthio group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q21)(Q22)(Q23), —N(Q21)(Q22), —B(Q21)(Q22), —C(═O)(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof; or
—Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32), and
Q1 to Q3, Q11 to Q13, Q21 to Q23, and Q31 to Q33 are each independently: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; a C1-C60 alkyl group; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; or a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a phenyl group, a biphenyl group, or any combination thereof.
According to an aspect of another embodiment, provided is a light-emitting device including: a first electrode; a second electrode facing the first electrode; an interlayer arranged between the first electrode and the second electrode and including an emission layer; and at least one of the condensed cyclic compound.
According to an aspect of another embodiment, provided is an electronic apparatus including the organic light-emitting device.
The above and other aspects, features, and advantages of certain embodiments of the disclosure will be more apparent from the following description taken in conjunction with the accompanying drawings, in which:
Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout the specification. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the figures, to explain aspects. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.
It will be understood that when an element is referred to as being “on” another element, it can be directly on the other element or intervening elements may be present therebetween In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present
It will be understood that, although the terms “first,” “second,” “third” etc. may be used herein to describe various elements, components, regions, layers and/or sections, these elements, components, regions, layers and/or sections should not be limited by these terms These terms are only used to distinguish one element, component, region, layer or section from another element, component, region, layer or section Thus, “a first element,” “component,” “region,” “layer” or “section” discussed below could be termed a second element, component, region, layer or section without departing from the teachings herein.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, “a,” “an,” “the,” and “at least one” do not denote a limitation of quantity, and are intended to cover both the singular and plural, unless the context clearly indicates otherwise. For example, “an element” has the same meaning as “at least one element,” unless the context clearly indicates otherwise.
“Or” means “and/or.” As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.
Furthermore, relative terms, such as “lower” or “bottom” and “upper” or “top,” may be used herein to describe one element's relationship to another element as illustrated in the Figures It will be understood that relative terms are intended to encompass different orientations of the device in addition to the orientation depicted in the Figures For example, if the device in one of the figures is turned over, elements described as being on the “lower” side of other elements would then be oriented on “upper” sides of the other elements The exemplary term “lower,” can therefore, encompasses both an orientation of “lower” and “upper,” depending on the particular orientation of the figure Similarly, if the device in one of the figures is turned over, elements described as “below” or “beneath” other elements would then be oriented “above” the other elements The exemplary terms “below” or “beneath” can, therefore, encompass both an orientation of above and below.
“About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within ±30%, 20%, 10% or 5% of the stated value.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features Moreover, sharp angles that are illustrated may be rounded Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.
An aspect of the present disclosure provides a condensed cyclic compound represented by Formulae 1-1 or 1-2:
wherein, in Formulae 1-1 and 1-2,
CY1 to CY3 may each independently be a C5-C60 carbocyclic group or a C1-C60 heterocyclic group.
In an embodiment, at least one of CY1 and CY2 may be a group represented by Formula 2-1 or 2-2.
In an embodiment, CY1 to CY3 may each independently be a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a thiophene group, a furan group, an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-one group, an azadibenzothiophene 5,5-dioxide group, an indolocarbazole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isooxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, a 5,6,7,8-tetrahydroquinoline group, or a group represented by Formula 2-1 or 2-2.
In an embodiment, the condensed cyclic compound represented by Formula 1-1 or 1-2 may satisfy at least one of Conditions 1 to 3:
Condition 1
CY1 is a group represented by Formula 2-1 or 2-2;
Condition 2
CY2 is a group represented by Formula 2-1 or 2-2; and
Condition 3
CY1 and CY2 are each independently a group represented by Formula 2-1 or 2-2.
In an embodiment, any two groups among CY1 to CY3 may be identical to each other.
In an embodiment, CY3 may be a benzene group, a naphthalene group, a dibenzosilole group, a carbazole group, a dibenzothiophene group, or a dibenzofuran group.
X1 may be O, S, Se, Te, N(R1a), or C(R1a)(R1b).
X2 may be O, S, Se, Te, N(R2a), or C(R2a)(R2b).
Y1 may be O, S, Se, Te, N(R3a), or C(R3a)(R3b).
Z1 may be B, Al, Si(R4a), Ge(R4a), P, P(═O), or P(═S).
In an embodiment, X1 may be O, and X2 may be O;
X1 may be S, and X2 may be S;
X1 may be Se, and X2 may be Se;
X1 may be Te, and X2 may be Te;
X1 may be N(R1a), and X2 may be N(R2a); or
X1 may be C(R1a)(R1b), and X2 may be C(R2a)(R2b).
In an embodiment, X1 and X2 may be identical to each other.
R1 to R3, R1a to R4a, and R1b to R3b may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2).
R1 to R3, R1a to R4a, and R1b to R3b may optionally be linked to each other or via a single bond to form a C8-C60 polycyclic group that is unsubstituted or substituted with at least one R10a.
d1 to d3 may each independently be an integer from 0 to 20.
In Formulae 2-1 and 2-2,
CY11 and CY12 may each independently be a C5-C60 carbocyclic group, a C1-C60 heterocyclic group, or a group represented by Formula 3.
One of the bonds marked with a dotted line in CY13 indicates a binding site to the bond marked with a solid line in CY1 or CY2.
In an embodiment, CY11 and CY12 may each independently be a benzene group or a group represented by Formula 3.
In Formula 3, CY4 to CY6 may each independently be a C5-C60 carbocyclic group or a C1-C60 heterocyclic group.
X4 may be O, S, Se, Te, N(R5a), or C(R5a)(R5b).
X5 may be O, S, Se, Te, N(R6a), or C(R6a)(R6b).
Z2 may be B, Al, Si(R7a), Ge(R7a), P, P(═O), or P(═S).
R5a to R7a, R5b, and R6b may each independently be the same as described in connection with R1a.
In an embodiment, a group represented by Formula 2-1 or 2-2 may be represented by one of Formulae 2-11 to 2-22:
wherein, in Formulae 2-11 to 2-22,
X31, X32, and Z31 may each be the same as described herein, and
one of the bonds marked with a dotted line in CY13 indicates a binding site to the bond marked with a solid line in CY1 or CY2.
In an embodiment, a moiety represented by
in Formula 1-1 may be represented by one of Formulae 3-1 to 3-8, and
a moiety represented by
in Formula 1-1 may be represented by one of Formulae 4-1 to 4-8, provided that when the moiety represented by
is represented by Formula 3-8 then the moiety represented by
is not represented by Formula 4-8:
wherein, in Formulae 3-1 to 3-8 and 4-1 to 4-8,
CY11 and CY12 may each be the same as described herein,
CY21 and CY22 may each be the same as described in connection with CY11,
R11 to R13 may each be the same as described in connection with R1,
R21 to R23 may each be the same as described in connection with R2,
d11, d12, d21, and d22 may each independently be an integer from 0 to 10,
d13 and d23 may each independently be an integer from 0 to 2,
d14 and d24 are each independently an integer from 0 to 4,
*1 indicates a binding site to X1 in Formula 1-1,
*′1 indicates a binding site to Z1 in Formula 1-1,
*2 indicates a binding site to X2 in Formula 1-1, and
*′2 indicates a binding site to Z1 in Formula 1-1.
In an embodiment, a moiety represented by
in Formula 1-2 may be represented by one of Formulae 3-11 to 3-16, and a moiety represented by
in Formula 1-2 may be represented by one of Formulae 4-11 to 4-16, provided that when the moiety represented by
is represented by Formula 3-16, then the moiety represented by
is not represented by Formula 4-16:
wherein, in Formulae 3-11 to 3-16 and 4-11 to 4-16,
CY11 and CY12 may each be the same as described herein,
CY21 and CY22 may each be the same as described in connection with CY11,
R11 to R13 may each be the same as described in connection with R1,
R21 to R23 may each be the same as described in connection with R2,
d11, d12, d21, and d22 may each independently be an integer from 0 to 10,
d14 and d24 are each independently an integer from 0 to 3,
*1 indicates a binding site to X1 in Formula 1-2,
*′1 indicates a binding site to Z1 in Formula 1-2,
*″1 indicates a binding site to Y1 in Formula 1-2,
*2 indicates a binding site to X2 in Formula 1-2,
*′2 indicates a binding site to Z1 in Formula 1-2, and
*″2 indicates a binding site to Y1 in Formula 1-2.
In an embodiment, the condensed cyclic compound represented by Formula 1-1 or 1-2 may be represented by one of Formulae 5-1 to 5-12 and 6-1 to 6-12:
wherein, in Formulae 5-1 to 5-12 and 6-1 to 6-12,
R11 to R13 may each be the same as described in connection with R1,
R21 to R23 and R26 to R28 may each be the same as described in connection with R2,
R31 may be the same as described in connection with R3,
d11, d15, d21, d26, and d28 may each independently be an integer from 0 to 3,
d12, d14, d22, d24, and d27 may each independently be an integer from 0 to 4,
d13, d23, and d25 may each independently be an integer from 0 to 2,
d31 may be an integer from 0 to 20,
Y2 may be the same as described in connection with Y1, and
CY3, X1, X2, Y1, Z1, X31, X32, and Z31 may each be the same as described herein.
In an embodiment, a moiety represented by
in Formula 1-1 may be represented by one of Formulae 3-1(1) to 3-10(1), and a moiety represented by
in Formula 1-1 may be represented by one of Formulae 4-1(1) to 4-10(1),
provided that when the moiety represented by
is represented by Formula 3-10(1), then the moiety represented by
is not represented by Formula 4-10(1):
In Formulae 3-1(1) to 3-10(1) and 4-1(1) to 4-10(1),
R11 to R13 may each be the same as described in connection with R1,
R21 to R23 may each be the same as described in connection with R2,
*1 indicates a binding site to X1 in Formula 1-1,
*′1 indicates a binding site to Z1 in Formula 1-1,
*2 indicates a binding site to X2 in Formula 1-1, and
*′2 indicates a binding site to Z1 in Formula 1-1.
In an embodiment, a moiety represented by
in Formula 1-2 may be represented by one of Formulae 3-11(1) to 3-16(1), and a moiety represented by
in Formula 1-2 may be represented by one of Formulae 4-11(1) to 4-16(1), provided that when the moiety represented by
is represented by Formula 3-16(1), then the moiety represented by
is not represented by Formula 4-16(1):
In Formulae 3-11(1) to 3-16(1) and 4-11(1) to 4-16(1),
R11 and R12 may each be the same as described in connection with R1,
R21 and R22 may each be the same as described in connection with R2,
*1 indicates a binding site to X1 in Formula 1-2,
*′1 indicates a binding site to Z1 in Formula 1-2,
*″1 indicates a binding site to Y1 in Formula 1-2,
*2 indicates a binding site to X2 in Formula 1-2,
*′2 indicates a binding site to Z1 in Formula 1-2, and
*″2 indicates a binding site to Y1 in Formula 1-2.
In an embodiment, a group represented by
in Formulae 1-1 and 1-2 may be represented by one of Formulae 7-1 to 7-3:
In Formulae 7-1 to 7-3,
indicates a binding site to X1 in Formula 1,
*′ indicates a binding site to Z1 in Formula 1,
*″ indicates a binding site to X2 in Formula 1,
X3 may be O, S, Se, Te, N(R31), or C(R31)(R32), and
R31 and R32 may each be the same as described in connection with R3.
In an embodiment, R1 to R3, R1a to R4a, and R1b to R3b may each independently be: hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, or a C1-C20 alkoxy group;
a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof;
a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, or an azadibenzosilolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof; or
—Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —CO(═)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2); and
Q1 to Q3 and Q31 to Q33 may each independently be:
—CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2; or
an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, a naphthyl group, a carbazole group, a dibenzofuranyl group, or a dibenzothiophenyl group, each unsubstituted or substituted with deuterium, a C1-C20 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, or any combination thereof.
In an embodiment, the condensed cyclic compound represented by Formula 1-1 or 1-2 may satisfy Equation 1:
E
R=[E(S0@ S1)]−[E(S0@S0)]≤0.1 eV Equation 1
wherein, in Equation 1, ER indicates the reorganization energy of the condensed cyclic compound, [E(S0@S1)] indicates the ground state energy of the condensed cyclic compound having a stable structure in an excited singlet state (S1), and [E(S0@S0)] indicates the ground state energy of the condensed cyclic compound having a stable structure in a ground state (S0).
Here, the stable structure and the energy are calculated using Gaussian 16 (Gaussian Inc.), and detailed calculation methods thereof are described below. In an embodiment, the condensed cyclic compound represented by Formula 1-1 or 1-2 may be one of Compounds 1 to 102, 201 to 203, 301 to 369, 401 to 413, and 501 to 532, but is not limited thereto:
In Compounds 1 to 102, 201 to 203, 301 to 369, 401 to 413, and 501 to 532, Ph indicates a phenyl group.
In the present specification, the term “R10a” may be:
deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group;
a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q11)(Q12)(Q13), —N(Q11)(Q12), —B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof;
a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, or a C6-C60 arylthio group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q21)(Q22)(Q23), —N(Q21)(Q22), —B(Q21)(Q22), —C(═O)(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof; or
—Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32), and
Q1 to Q3, Q11 to Q13, Q21 to Q23, and Q31 to Q33 may each independently be: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; a C1-C60 alkyl group; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; or a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a phenyl group, a biphenyl group, or any combination thereof.
The condensed cyclic compound represented by Formula 1-1 or 1-2 of the present disclosure has a nitrogen atom (N) having an electron-donating property and a boron atom (B) having an electron-accepting property. In this regard, the multiple resonance between the atoms may be further activated so that the compound may have a structure in which the delocalization of electrons in the molecule is expanded. Also, in addition to such an electronic effect by the arrangement, the compound is also structurally stable so that the molecular structure change between the ground state (S0) and the first excited singlet state (S1), which causes broadening of the emission spectrum, may be suppressed. As a result, the condensed cyclic compound may emit light having high color purity with a narrow spectrum, in particular, blue light emission having high purity with a narrow spectrum.
In addition, the condensed cyclic compound may include at least one partial structure represented by Formula 2-1 or 2-2. Accordingly, the electronic effect by the arrangement also contributes to further increasing the oscillator strength (f) (hereinafter, also referred to as “oscillator strength f”) of the stable structure in the first excited singlet state (S1), which is an index of fluorescence strength, thereby realizing sufficient luminescence efficiency along with high color purity.
Therefore, a light-emitting device, e.g., an organic light-emitting device, using the condensed cyclic compound represented by Formula 1-1 or 1-2 may have a low driving voltage, high maximum quantum efficiency, high efficiency, and a long lifespan.
Synthesis methods of the condensed cyclic compound represented by Formula 1-1 or 1-2 may be recognized by one of ordinary skill in the art by referring to Examples provided below.
At least one organometallic compound represented by Formula 1-1 or 1-2 may be used in a light-emitting device (for example, an organic light-emitting device).
An aspect of the present disclosure provides a composition including at least one condensed cyclic compound.
In an embodiment, the composition may further include a solvent.
In an embodiment, the solvent may have a boiling point of 100° C. or more and 350° C. or less at atmospheric pressure (101.3 kPa, 1 atm).
In an embodiment, the boiling point of the solvent at atmospheric pressure may be 150° C. or more and 320° C. or less, for example, 180° C. or more and 300° C. or less.
When the boiling point of the solvent at atmospheric pressure is within these ranges, a wet film-forming method, particularly in terms of film formability or processability in the inkjet method, may be improved.
The solvent having a boiling point of 100° C. or more and 350° C. or less is not particularly limited, and any well-known solvent may be used suitably. A list of solvents having a boiling point of 100° C. or more and 350° C. or less at atmospheric pressure is provided below, but embodiments of the present disclosure are not limited thereto.
Examples of a hydrocarbon-based solvent are octane, nonane, decane, undecane dodecane, and the like. Examples of an aromatic hydrocarbon-based solvent are toluene, xylene, ethylbenzene, n-propylbenzene, iso-propylbenzene (1-butylbenzoate), and the like. Examples of a nitrile-based solvent are benzonitrile, 3-methylbenzonitrile, and the like. Examples of an amide-based solvent are dimethylformamide, dimethylacetamide, N-methylpyrrolidone, and the like. These solvents may be used alone or in combination of two or more types.
Another aspect of the present disclosure provides a light-emitting device including: a first electrode; a second electrode facing the first electrode; an interlayer arranged between the first electrode and the second electrode and including an emission layer; and at least one condensed cyclic compound.
In an embodiment, the first electrode may be an anode, the second electrode may be a cathode, and the interlayer may further include a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode, wherein the hole transport region may include a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or any combination thereof, and the electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.
In an embodiment, the emission layer may include the at least one condensed cyclic compound.
In an embodiment, the emission layer may include a host and a dopant,
wherein the host and the dopant may be different from each other,
an amount of the host may be greater than that of the dopant, and
the dopant may include the at least one condensed cyclic compound.
In an embodiment, the emission layer may further include a sensitizer.
In an embodiment, the sensitizer may be an organometallic compound. For example, the sensitizer may be an organometallic compound including Pt as a central metal, but is not limited thereto. More details for the sensitizer are the same as described herein.
In an embodiment, the emission layer may further include a host and a light-emitting dopant, and the at least one condensed cyclic compound may be a sensitizer. Here, the amount of the host in the emission layer may be greater than the total amount of the light-emitting dopant and the sensitizer. The host will be described in detail. When the condensed cyclic compound is used as a sensitizer, the energy transferred to the triplet may cross inversely to the singlet, and then the singlet energy of the condensed cyclic compound may be transferred to the dopant through the Förster energy transfer. Accordingly, the efficiency and lifespan of an organic light-emitting device may be improved at the same time.
In an embodiment, the emission layer may emit blue light or blue-green light.
In an embodiment, the emission layer may emit light having a maximum emission wavelength in a range of about 400 nm to about 500 nm.
The expression “(an interlayer) includes at least one condensed-cyclic compound” as used herein may include a case in which “(an interlayer) includes identical condensed cyclic compounds represented by Formula 1-1 or 1-2 or a case in which “(an interlayer) includes two or more different condensed cyclic compounds represented by Formula 1-1 or 1-2”.
For example, the interlayer may include, as the condensed cyclic compound, only Compound 1. In this embodiment, Compound 1 may be included in the emission layer of the organic light-emitting device. In one or more embodiments, the interlayer may include, as the condensed cyclic compound, Compound 1 and Compound 2. In this regard, Compound 1 and Compound 2 may exist in an identical layer (for example, Compound 1 and Compound 2 may all exist in the emission layer), or may exist in different layers (for example, Compound 1 may exist in the emission layer and Compound 2 may exist in the electron transport region).
The term “interlayer” as used herein refers to a single layer and/or all of a plurality of layers arranged between the first electrode and the second electrode of the light-emitting device.
The term “sensitizer” as used herein refers to a compound that is included in an interlayer (for example, an emission layer) and delivers excitation energy to a light-emitting dopant compound.
Another aspect of the present disclosure provides an electronic apparatus including the organic light-emitting device.
More details for the electronic apparatus are the same as described herein.
The organic light-emitting device 10 of
In the organic light-emitting device 10, a hole transport region 3 is arranged between the first electrode 2 and the emission layer 4, and an electron transport region 5 is arranged between the emission layer 4 and the second electrode 6.
Also, the substrate 1 may be additionally arranged under the first electrode 2 or above the second electrode 6. For use as the substrate 1, any substrate that is used in organic light-emitting devices available in the art may be used, and for example, a glass substrate or a transparent plastic substrate, each having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance, may be used.
The first electrode 2 may be formed by, for example, depositing or sputtering a material for forming the first electrode 2 on the substrate 1. The first electrode 2 may be an anode. The material for forming the first electrode 2 may be materials with a high work function to facilitate hole injection.
The first electrode 2 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. When the first electrode 2 is a transmissive electrode, the material for forming the first electrode 2 may be indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO2), zinc oxide (ZnO), or any combination thereof, but embodiments of the present disclosure are not limited thereto. When the first electrode 2 is a semi-transmissive electrode or a reflective electrode, the material for forming the first electrode 2 may be magnesium (Mg), silver (Ag), aluminum (AI), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), magnesium-silver (Mg—Ag), or any combination thereof, but embodiments of the present disclosure are not limited thereto.
The first electrode 2 may have a single-layered structure or a multi-layered structure including two or more layers.
The emission layer 4 may be a single layer consisting of a single material or a single layer consisting of a plurality of different materials. In addition, the emission layer 4 may have a multi-layered structure including a plurality of layers including different materials.
The emission layer 4 may include the condensed cyclic compound represented by Formula 1-1 or 1-2.
A thickness of the emission layer 4 may be in a range of about 10 Å to about 1,000 Å, for example, about 100 Å to about 300 Å. When the thickness of the emission layer 4 is within these ranges, excellent luminescence characteristics may be obtained without a substantial increase in driving voltage.
In an embodiment, the emission layer 4 of the organic light-emitting device 10 may include, in addition to the condensed cyclic compound represented by Formula 1-1 or 1-2, an anthracene derivative, a pyrene derivative, a fluoranthene derivative, a chrysene derivative, a dihydrobenzoanthracene derivative, a triphenylene derivative, or any combination thereof.
In an embodiment, the emission layer 4 of the organic light-emitting device 10 may include a host and a dopant.
In an embodiment, the host may include one kind of host. When the host includes one kind of host, the one kind of host may be a bipolar host, an electron-transporting host, a hole-transporting host, or any combination thereof, each of which will be described later.
In an embodiment, the host may have a highest occupied molecular orbital (HOMO) energy level of equal to or less than −5.2 eV and a lowest unoccupied molecular orbital (LUMO) energy level of equal to or less than −1.4 eV. By using a host material having low HOMO and LUMO energy levels and high electron transport properties, an organic light-emitting device, particularly a blue organic light-emitting device, may have advantages such as improved driving durability.
In one or more embodiments, the host may include a mixture of two types of materials different from each other. For example, the host may be a mixture of an electron-transporting host and a hole-transporting host, a mixture of two types of electron-transporting hosts different from each other, or a mixture of two types of hole-transporting hosts different from each other. The electron-transporting host and the hole-transporting host will be described in detail below.
In one or more embodiments, the host may include an electron-transporting host including at least one electron-transporting moiety and a hole-transporting host that is free of an electron-transporting moiety.
The electron-transporting moiety used herein may be a cyano group, a π electron-deficient nitrogen-containing cyclic group, or a group represented by one of the following formulae:
In the formulae above, *, *′, and *″ each indicate a binding site to a neighboring atom.
In one or more embodiments, the electron-transporting host of the emission layer 4 may include at least one of a cyano group, a π electron-deficient nitrogen-containing cyclic group, or any combination thereof.
In one or more embodiments, the electron-transporting host in the emission layer 4 may include at least one cyano group.
In one or more embodiments, the electron-transporting host in the emission layer 4 may include at least one cyano group, at least one π electron deficient nitrogen-containing cyclic group, or any combination thereof.
In one or more embodiments, the host may include an electron-transporting host and a hole-transporting host, wherein the electron-transporting host may include at least one π electron-deficient nitrogen-free cyclic group, at least one electron-transporting moiety, or any combination thereof, and the hole-transporting host may include at least one π electron-deficient nitrogen-free cyclic group, and may not include an electron-transporting moiety.
The term “π electron-deficient nitrogen-containing cyclic group” as used herein refers to a cyclic group having at least one *—N=*′ moiety, and for example, may be: an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyridazine group, a pyrimidine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an isobenzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, an azacarbazole group, or a condensed cyclic group in which two or more π electron-efficient nitrogen-containing cyclic groups are condensed with each other.
The π electron-deficient nitrogen-free cyclic group may be: a benzene group, a heptalene group, an indene group, a naphthalene group, an azulene group, an indacene group, an acenaphthylene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentacene group, a hexacene group, a pentacene group, a rubicene group, a corogen group, an ovalene group, a pyrrole group, an isoindole group, an indole group, a furan group, a thiophene group, a benzofuran group, a benzothiophene group, a benzocarbazole group, a dibenzocarbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzothiophene sulfone group, a carbazole group, a dibenzosilole group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, a triindolobenzene group; or a condensed cyclic group of two or more π electron-deficient nitrogen-free cyclic groups, but embodiments of the present disclosure are not limited thereto.
In one or more embodiments, the electron-transporting host may be a compound represented by Formula E-1, and
the hole-transporting host may be a compound represented by Formula H-1, but embodiments of the present disclosure are not limited thereto:
[Ar301]xb11-[(L301)xb1-R301]xb21
wherein, in Formula E-1,
Ar301 may be a substituted or unsubstituted C5-C60 carbocyclic group and a substituted or unsubstituted C1-C60 heterocyclic group,
xb11 may be 1, 2, or 3,
L301 may be a single bond, a group represented by one of the following formulae, a substituted or unsubstituted C5-C60 carbocyclic group, or a substituted or unsubstituted C1-C60 heterocyclic group, wherein *, *′, and *″ in the formulae each indicate a binding site to a neighboring atom,
wherein, in the formulae above, xb1 may be an integer from 1 to 5,
R301 may be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —Si(Q301)(Q302)(Q303), —N(Q301)(Q302), —B(Q301)(Q302), —C(═O)(Q301), —S(═O)2(Q301), —S(═O)(Q301), —P(═O)(Q301)(Q302), or —P(═S)(Q301)(Q302),
xb21 may be an integer from 1 to 5,
Q301 to Q303 may each independently be a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group, and
at least one of Conditions H-1 to H-3 may be satisfied:
Condition H-1
Ar301, L301, and R301 in Formula E-1 may each independently include a π electron-deficient nitrogen-containing cyclic group;
Condition H-2
L301 in Formula E-1 is a group represented by one of the following formulae; and
Condition H-3
R301 in Formula E-1 may be a cyano group, —S(═O)2(Q301), —S(═O)(Q301), —P(═O)(Q301)(Q302), and —P(═S)(Q301)(Q302),
Ar401-(L401)xd1-(Ar402)xd11 Formula H-1
wherein, in Formulae H-1, 11, and 12,
L401 may be:
a single bond; or
a benzene group, a heptalene group, an indene group, a naphthalene group, an azulene group, an indacene group, an acenaphthylene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentacene group, a hexacene group, a pentacene group, a rubicene group, a corogen group, an ovalene group, a pyrrole group, an isoindole group, an indole group, a furan group, a thiophene group, a benzofuran group, a benzothiophene group, a benzocarbazole group, a dibenzocarbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzothiophene sulfone group, a carbazole group, a dibenzosilole group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, and a triindolobenzene group, each unsubstituted or substituted with at least one of deuterium, a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a triphenylenyl group, a biphenyl group, a terphenyl group, a tetraphenyl group, or —Si(Q401)(Q402)(Q403),
xd1 may be an integer from 1 to 10, wherein, when xd1 is 2 or more, two or more of L401(s) may be identical to or different from each other,
Ar401 may be a group represented by Formulae 11 or 12,
Ar402 may be:
a group represented by Formulae 11 or 12, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group; or
a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group, each substituted with at least one deuterium, a hydroxyl group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid or a salt thereof, a sulfonic acid or a salt thereof, a phosphoric acid or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, a triphenylenyl group, or any combination thereof,
CY401 and CY402 may each independently be a benzene group, a naphthalene group, a fluorene group, a carbazole group, a benzocarbazole group, an indolocarbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzosilole group, a benzonaphthofuran group, a benzonaphthothiophene group, or a benzonaphthosilole group,
A21 may be a single bond, O, S, N(R51), C(R51)(R52), or Si(R51)(R52),
A22 may be a single bond, O, S, N(R53), C(R53)(R54), or Si(R53)(R54),
at least one of A21, A22, or any combination thereof in Formula 12 may not be a single bond,
R51 to R54, R60, and R70 may each independently be:
hydrogen, deuterium, a hydroxyl group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, or a C1-C20 alkoxy group;
a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with at least one deuterium, a hydroxyl group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, or any combination thereof;
a π electron-deficient nitrogen-free cyclic group (for example, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group);
a π electron-deficient nitrogen-free cyclic group (for example, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group), each substituted with at least one deuterium, a hydroxyl group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid or a salt thereof, a sulfonic acid or a salt thereof, a phosphoric acid or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, or any combination thereof, or
—Si(Q404)(Q405)(Q406),
e1 and e2 may each independently be an integer from 0 to 10,
Q401 to Q406 may each independently be hydrogen, deuterium, a hydroxyl group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid or a salt thereof, a sulfonic acid or a salt thereof, a phosphoric acid or a salt thereof, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group, and
* indicates a binding site to a neighboring atom.
In an embodiment, Ar301 and L301 in Formula E-1 may each independently be a benzene group, a naphthalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, a dibenzofuran group, a dibenzothiophene group, an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyridazine group, a pyrimidine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an isobenzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, or an azacarbazole group, each unsubstituted or substituted with at least one deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a cyano-containing phenyl group, a cyano-containing biphenyl group, a cyano-containing terphenyl group, a cyano-containing naphthyl group, a pyridinyl group, a phenylpyridinyl group, a diphenylpyridinyl group, a biphenylpyridinyl group, a di(biphenyl)pyridinyl group, a pyrazinyl group, a phenylpyrazinyl group, a diphenylpyrazinyl group, a biphenylpyrazinyl group, a di(biphenyl)pyrazinyl group, a pyridazinyl group, a phenylpyridazinyl group, a diphenylpyridazinyl group, a biphenylpyridazinyl group, a di(biphenyl)pyridazinyl group, a pyrimidinyl group, a phenylpyrimidinyl group, a diphenylpyrimidinyl group, a biphenylpyrimidinyl group, a di(biphenyl)pyrimidinyl group, a triazinyl group, a phenyltriazinyl group, a diphenyltriazinyl group, a biphenyltriazinyl group, a di(biphenyl)triazinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof,
at least one of the L301(s) in the number of xb1 may each independently be an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyridazine group, a pyrimidine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an isobenzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, or an azacarbazole group, each unsubstituted or substituted with at least one deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a cyano-containing phenyl group, a cyano-containing biphenyl group, a cyano-containing terphenyl group, a cyano-containing naphthyl group, a pyridinyl group, a phenylpyridinyl group, a diphenylpyridinyl group, a biphenylpyridinyl group, a di(biphenyl)pyridinyl group, a pyrazinyl group, a phenylpyrazinyl group, a diphenylpyrazinyl group, a biphenylpyrazinyl group, a di(biphenyl)pyrazinyl group, a pyridazinyl group, a phenylpyridazinyl group, a diphenylpyridazinyl group, a biphenylpyridazinyl group, a di(biphenyl)pyridazinyl group, a pyrimidinyl group, a phenylpyrimidinyl group, a diphenylpyrimidinyl group, a biphenylpyrimidinyl group, a di(biphenyl)pyrimidinyl group, a triazinyl group, a phenyltriazinyl group, a diphenyltriazinyl group, a biphenyltriazinyl group, a di(biphenyl)triazinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof,
R301 may be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a tetraphenyl group, a naphthyl group, a cyano-containing phenyl group, a cyano-containing biphenyl group, a cyano-containing terphenyl group, a cyano-containing tetraphenyl group, a cyano-containing naphthyl group, a pyridinyl group, a phenylpyridinyl group, a diphenylpyridinyl group, a biphenylpyridinyl group, a di(biphenyl)pyridinyl group, a pyrazinyl group, a phenylpyrazinyl group, a diphenylpyrazinyl group, a biphenylpyrazinyl group, a di(biphenyl)pyrazinyl group, a pyridazinyl group, a phenylpyridazinyl group, a diphenylpyridazinyl group, a biphenylpyridazinyl group, a di(biphenyl)pyridazinyl group, a pyrimidinyl group, a phenylpyrimidinyl group, a diphenylpyrimidinyl group, a biphenylpyrimidinyl group, a di(biphenyl)pyrimidinyl group, a triazinyl group, a phenyltriazinyl group, a diphenyltriazinyl group, a biphenyltriazinyl group, a di(biphenyl)triazinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32), and
Q31 to Q33 may each independently be a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group, but embodiments of the present disclosure are not limited thereto.
In one or more embodiments,
Ar301 may be a benzene group, a naphthalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, a dibenzofuran group, or a dibenzothiophene group, each unsubstituted or substituted with at least one deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a cyano-containing phenyl group, a cyano-containing biphenyl group, a cyano-containing terphenyl group, a cyano-containing naphthyl group, a pyridinyl group, a phenylpyridinyl group, a diphenylpyridinyl group, a biphenylpyridinyl group, a di(biphenyl)pyridinyl group, a pyrazinyl group, a phenylpyrazinyl group, a diphenylpyrazinyl group, a biphenylpyrazinyl group, a di(biphenyl)pyrazinyl group, a pyridazinyl group, a phenylpyridazinyl group, a diphenylpyridazinyl group, a biphenylpyridazinyl group, a di(biphenyl)pyridazinyl group, a pyrimidinyl group, a phenylpyrimidinyl group, a diphenylpyrimidinyl group, a biphenylpyrimidinyl group, a di(biphenyl)pyrimidinyl group, a triazinyl group, a phenyltriazinyl group, a diphenyltriazinyl group, a biphenyltriazinyl group, a di(biphenyl)triazinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32). or any combination thereof; or
a group represented by one of Formulae 5-1 to 5-3 and 6-1 to 6-33, and
L301 may be a group represented by one of Formulae 5-1 to 5-3 and 6-1 to 6-33:
wherein, in Formulae 5-1 to 5-3 and 6-1 to 6-33,
Z1 may be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a cyano-containing phenyl group, a cyano-containing biphenyl group, a cyano-containing terphenyl group, a cyano-containing naphthyl group, a pyridinyl group, a phenylpyridinyl group, a diphenylpyridinyl group, a biphenylpyridinyl group, a di(biphenyl)pyridinyl group, a pyrazinyl group, a phenylpyrazinyl group, a diphenylpyrazinyl group, a biphenylpyrazinyl group, a di(biphenyl)pyrazinyl group, a pyridazinyl group, a phenylpyridazinyl group, a diphenylpyridazinyl group, a biphenylpyridazinyl group, a di(biphenyl)pyridazinyl group, a pyrimidinyl group, a phenylpyrimidinyl group, a diphenylpyrimidinyl group, a biphenylpyrimidinyl group, a di(biphenyl)pyrimidinyl group, a triazinyl group, a phenyltriazinyl group, a diphenyltriazinyl group, a biphenyltriazinyl group, a di(biphenyl)triazinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32),
d4 may be 0, 1, 2, 3, or 4,
d3 may be 0, 1, 2, or 3,
d2 may be 0, 1, or 2,
* and *′ each indicate a binding site to a neighboring atom, and
Q31 to Q33 may each be the same as described above.
In one or more embodiments, L301 may be a group represented by one of Formulae 5-2, 5-3, and 6-8 to 6-33.
In one or more embodiments, R301 may be a cyano group or a group represented by one of Formula 7-1 to 7-18, and at least one of the Ar402(s) in the number of xd11 may be a group represented by one of Formulae 7-1 to 7-18, but embodiments of the present disclosure are not limited thereto:
wherein, in Formulae 7-1 to 7-18,
xb41 to xb44 may each be 0, 1, or 2, wherein xb41 in Formula 7-10 is not 0, the sum of xb41 and xb42 in Formulae 7-11 to 7-13 is not 0, the sum of xb41, xb42, and xb43 in Formulae 7-14 to 7-16 is not 0, the sum of xb41, xb42, xb43, and xb44 in Formulae 7-17 and 7-18 is not 0, and * indicates a binding site to a neighboring atom.
Two or more Ar301(s) in Formula E-1 may be identical to or different from each other, two or more L301(s) may be identical to or different from each other, two or more L401(s) in Formula H-1 may be identical to or different from each other, and two or more Ar402(s) in Formula H-1 may be identical to or different from each other.
In an embodiment, the electron-transporting host may include i) at least one of a cyano group, a pyrimidine group, a pyrazine group, a triazine group, or any combination thereof, or ii) a triphenylene group, and the hole-transporting host may include a carbazole group.
In one or more embodiments, the electron-transporting host may include at least one cyano group.
The electron-transporting host may be, for example, a compound of Groups HE1 to HE7, but embodiments of the present disclosure are not limited thereto:
In one or more embodiments, the electron-transporting host may include DPEPO, mCBP-1CN, or mCBP-2CN:
In one or more embodiments, the hole-transporting host may be one of Compounds H-H1 to H-H103, but embodiments of the present disclosure are not limited thereto:
In one or more embodiments, the bipolar host may be of Group HEH1, but embodiments of the present disclosure are not limited thereto:
wherein, in Compounds 1 to 432, Ph indicates a phenyl group.
In one or more embodiments, the hole-transporting host may include o-CBP:
When the host is a mixture of an electron-transporting host and a hole-transporting host, a weight ratio of the electron-transporting host and the hole-transporting host may be in a range of 1:9 to 9:1, for example, 2:8 to 8:2, for example, 4:6 to 6:4, and for example, 5:5. When the weight ratio of the electron-transporting host and the hole-transporting host is satisfied with these ranges, the balance between holes and electrons in the emission layer 4 may be made.
In an embodiment, the host may include at least one of TPBi, TBADN, ADN (also referred to as “DNA”), CBP, CDBP, TCP, mCP, Compounds H50 to H52, or any combination thereof:
In one or more embodiments, the host may further include a compound represented by Formula 301:
wherein, in Formula 301, Ar111 and Ar112 may each independently be:
a phenylene group, a naphthylene group, a phenanthrenylene group, or a pyrenylene group; or
a phenylene group, a naphthylene group, a phenanthrenylene group, or a pyrenylene group, each substituted with at least one of a phenyl group, a naphthyl group, an anthracenyl group, or any combination thereof.
In Formula 301, Ar113 to Ar116 may each independently be:
a C1-C10 alkyl group, a phenyl group, a naphthyl group, a phenanthrenyl group, or a pyrenyl group; or
a phenyl group, a naphthyl group, a phenanthrenyl group, or a pyrenyl group, each substituted with at least one of a phenyl group, a naphthyl group, an anthracenyl group, or any combination thereof.
In Formula 301, g, h, i, and j may each independently be an integer from 0 to 4, and for example, may be 0, 1, or 2.
In Formula 301, Ar113 and Ar116 may each independently be:
a C1-C10 alkyl group substituted with at least one of a phenyl group, a naphthyl group, an anthracenyl group, or any combination thereof;
a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl, a phenanthrenyl group, or a fluorenyl group;
a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, or a fluorenyl group, each substituted with at least one deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, a fluorenyl group, or any combination thereof; or
but embodiments of the present disclosure are not limited thereto.
In one or more embodiments, the host may include a compound represented by Formula 302:
wherein, in Formula 302, Ar122 to Ar125 may each be the same as described in connection with Ar113 in Formula 301.
In Formula 302, Ar126 and Ar127 may each independently be a C1-C10 alkyl group (for example, a methyl group, an ethyl group, or a propyl group).
In Formula 302, k and l may each independently be an integer from 0 to 4. For example, k and l may each independently be 0, 1, or 2.
When the organic light-emitting device 10 is a full-color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and a blue emission layer. In an embodiment, based on a stacked structure including a red emission layer, a green emission layer, and/or a blue emission layer, the emission layer may emit white light, and various modifications are possible.
When the emission layer includes both a host and a dopant, an amount of the dopant may be in a range of about 0.01 parts by weight to about 15 parts by weight based on 100 parts by weight of the host, but embodiments of the present disclosure are not limited thereto.
The dopant may include the condensed cyclic compound represented by Formula 1-1 or 1-2.
In an embodiment, the dopant may be 1,4-bis[2-(3-N-ethylcarbazolyl)-vinyl]benzene (BCzVB), 4-(di-p-tolylamino)-4′-[(di-p-tolylamino)styryl]stilbene (DPAVB), N-(4-((E)-2-(6-((E)-4-(diphenylamino)styryl)naphthalene-2-yl)vinyl)phenyl)-N-phenylbenzeneamine (N-BDAVBi), 2,5,8,11-tetra-t-butylperylene (TBP), or any combination thereof.
In an embodiment, the sensitizer may include a phosphorescent sensitizer including at least one metal a first-row transition metal of the Periodic Table of Elements, a second-row transition metal of the Periodic Table of Elements, third-row transition metal of the Periodic Table of Elements, or any combination thereof.
In an embodiment, the sensitizer may include an organic ligand (L11) and a metal (M11) of at least one of a first-row transition metal of the Periodic Table of Elements, a second-row transition metal of the Periodic Table of Elements, a third-row transition metal of the Periodic Table of Elements, or any combination thereof wherein L11 and M11 may form one cyclometallated ring or two, three, or four cyclometallated rings.
In an embodiment, the sensitizer may include an organometallic compound represented by Formula 101:
M11(L11)n11(L12)n12 Formula 101
wherein, in Formula 101,
M11 may be a first-row transition metal of the Periodic Table of Elements, a second-row transition metal of the Periodic Table of Elements, or a third-row transition metal of the Periodic Table of Elements,
L11 may be a ligand represented by one of Formulae 13-1 to 13-4,
L12 may be a monodentate ligand or a bidentate ligand,
n11 may be 1,
n12 may be 0, 1, or 2,
wherein, in Formulae 13-1 to 13-4,
A1 to A4 may each independently be a substituted or unsubstituted C5-C30 carbocyclic group, a substituted or unsubstituted O1—O30 heterocyclic group, or a non-cyclic group,
Y11 to Y14 may each independently be a chemical bond, O, S, N(R91), B(R91), P(R91), or C(R91)(R92),
T1 to T4 may each independently be a single bond, a double bond, *—N(R93)—*′, *—B(R93)—*′, *—P(R93)—*′, *—C(R93)(R94)—*′, *—Si(R93)(R94)—*′, *—Ge(R93)(R94)—*′, *—S*′, *—Se—*′, *—O—*′, *—C(═O)—*′, *—S(═O)—*′, *—S(═O)2—*′ *—C(R93)=*′, *═C(R93)—*′, *—C(R93)═C(R94)—*′, *—C(═S)—*′, or *—C≡C—*′,
a substituent of the substituted C5-C30 carbocyclic group, a substituent of substituted C1-C30 heterocyclic group, and R9, to R94 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, —SF5, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid or a salt thereof, a sulfonic acid or a salt thereof, a phosphoric acid or a salt thereof, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent aromatic condensed polycyclic group, a substituted or unsubstituted monovalent aromatic heteropolycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —Si(Q1)(Q2)(Q3), —Ge(Q1)(Q2)(Q3), —C(Q1)(Q2)(Q3), —B(Q1)(Q2), —N(Q1)(Q2), —P(Q1)(Q2), —C(═O)(Q1), —S(═O)(Q1), —S(═O)2(Q1), —P(═O)(Q1)(Q2), or —P(═S)(Q1)(Q2), wherein each of a substituent of the substituted C5-C30 carbocyclic group and a substituent of substituted C1-C30 heterocyclic group is not hydrogen,
*1, *2, *3, and *4 each indicate a binding site to M11, and
Q1 to Q3 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C7-C60 alkylaryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a C2-C60 alkyl heteroaryl group, a C1-C60 heteroaryloxy group, a C1-C60 heteroarylthio group, a monovalent aromatic condensed polycyclic group, a monovalent aromatic heteropolycyclic group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, a C1-C60 alkyl group that is substituted with at least one deuterium, —F, a cyano group, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof, or a C6-C60 aryl group that is substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof.
In one or more embodiments, the sensitizer may be of Groups I to IX, but embodiments of the present disclosure are not limited thereto:
In one or more embodiments, the sensitizer may include Compound Pt1, but embodiments of the present disclosure are not limited thereto:
In one or more embodiments, the sensitizer may be represented by Formula 102 or 103, and in this case, the sensitizer may be referred to as a delayed fluorescence sensitizer:
wherein, in Formulae 102 and 103,
A21 may be an acceptor group,
D21 may be a donor group,
m21 may be 1, 2, or 3, and n21 may be 1, 2, or 3,
the sum of n21 and m21 in Formula 101 may be 6 or less, and the sum of n21 and m21 in Formula 102 may be 5 or less,
R21 may be hydrogen, deuterium, —F, —Cl, —Br, —I, SF5, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C7-C60 alkylaryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 alkylheteroaryl group, a substituted or unsubstituted C2-C60 heteroaryl alkyl group, a substituted or unsubstituted C1-C60 heteroaryloxy group, a substituted or unsubstituted C1-C60 heteroarylthio group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —Si(Q1)(Q2)(Q3), —Ge(Q1)(Q2)(Q3), —C(Q1)(Q2)(Q3), —B(Q1)(Q2), —N(Q1)(Q2), —P(Q1)(Q2), —C(═O)(Q1), —S(═O)(Q1), —S(═O)2(Q1), —P(═O)(Q1)(Q2), or —P(═S)(Q1)(Q2), wherein a plurality of R21(s) may optionally be linked to each other to form a substituted or unsubstituted C5-C30 carbocyclic group or a substituted or unsubstituted C1-C30 heterocyclic group, and
Q1 to Q3 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C7-C60 alkylaryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a C2-C60 alkyl heteroaryl group, a C1-C60 heteroaryloxy group, a C1-C60 heteroarylthio group, a monovalent aromatic condensed polycyclic group, a monovalent aromatic heteropolycyclic group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, a C1-C60 alkyl group that is substituted with at least one deuterium, —F, a cyano group, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof, or a C6-C60 aryl group that is substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof.
For example, A21 in Formulae 102 and 103 may be a substituted or unsubstituted π electron-deficient nitrogen-free cyclic group.
In an embodiment, the π electron-deficient nitrogen-free cyclic group may be: a benzene group, a heptalene group, an indene group, a naphthalene group, an azulene group, an indacene group, an acenaphthylene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentacene group, a hexacene group, a pentacene group, a rubicene group, a corogen group, an ovalene group, a pyrrole group, an isoindole group, an indole group, a furan group, a thiophene group, a benzofuran group, a benzothiophene group, a benzocarbazole group, a dibenzocarbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzothiophene sulfone group, a carbazole group, a dibenzosilole group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, a triindolobenzene group; or a condensed cyclic group of two or more π electron-deficient nitrogen-free cyclic groups, but embodiments of the present disclosure are not limited thereto.
For example, D21 in Formulae 102 and 103 may be: —F, a cyano group, or an π-electron deficient nitrogen-containing cyclic group;
a C1-C60 alkyl group, an π-electron deficient nitrogen-containing cyclic group, or an π electron-deficient nitrogen-free cyclic group, each substituted with at least one —F a cyano group, or any combination thereof; or
an π-electron deficient nitrogen-containing cyclic group, each substituted with at least one deuterium, a C1-C60 alkyl group, an π-electron deficient nitrogen-containing cyclic group, an π electron-deficient nitrogen-free cyclic group, or any combination thereof.
In detail, the π electron-deficient nitrogen-free cyclic group may be the same as described above.
The term “π electron-deficient nitrogen-containing cyclic group” as used herein refers to a cyclic group having at least one *—N=*′ moiety, and, for example, may be: an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyridazine group, a pyrimidine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an isobenzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, an azacarbazole group, and a benzimidazolobenzimidazole group, or a condensed cyclic group in which two or more π electron-efficient nitrogen-containing cyclic groups are condensed with each other.
In one or more embodiments, the sensitizer may be of Groups X to XV, but embodiments of the present disclosure are not limited thereto:
Hole transport region 3
In the organic light-emitting device 10, the hole transport region 3 may be arranged between the first electrode 2 and the emission layer 4.
The hole transport region 3 may have a single-layered structure or a multi-layered structure.
For example, the hole transport region 3 may have a hole injection layer, a hole transport layer, a hole injection layer/hole transport layer structure, a hole injection layer/first hole transport layer/second hole transport layer structure, a hole transport layer/interlayer structure, a hole injection layer/hole transport layer/interlayer structure, a hole transport layer/electron blocking layer structure, or a hole injection layer/hole transport layer/electron blocking layer structure, but embodiments of the present disclosure are not limited thereto.
The hole transport region 3 may include any compound having hole-transporting properties.
For example, the hole transport region 3 may include a carbazole-based compound, such as N-phenyl carbazole and polyvinyl carbazole, a fluorene-based compound, Compound H1, Compound H2, or any combination thereof.
For example, the hole transport region 3 may include an amine-based compound.
In an embodiment, the hole transport region 3 may include at least one compound represented by Formulae 201 to 205, but embodiments of the present disclosure are not limited thereto:
wherein, in Formulae 201 to 205,
L201 to L209 may each independently *-be O—*′, *—S—*′, a substituted or unsubstituted C5-C60 carbocyclic group, or a substituted or unsubstituted C1-C60 heterocyclic group,
xa1 to xa9 may each independently be an integer from 0 to 5, and
R201 to R206 may each independently be a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, wherein neighboring two groups of R201 to R206 may optionally be linked to each other via a single bond, a dimethyl-methylene group, or a diphenyl-methylene group.
For example, L201 to L209 may be:
a benzene group, a heptalene group, an indene group, a naphthalene group, an azulene group, a heptalene group, an indacene group, an acenaphthylene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentacene group, a hexacene group, a pentacene group, a rubicene group, a corogen group, an ovalene group, a pyrrole group, an isoindole group, an indole group, a furan group, a thiophene group, a benzofuran group, a benzothiophene group, a benzocarbazole group, a dibenzocarbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzothiophene sulfone group, a carbazole group, a dibenzosilole group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, and a triindolobenzene group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a triphenylenyl group, a biphenyl group, a terphenyl group, a tetraphenyl group, or —Si(Q11)(Q12)(Q13),
xa1 to xa9 may each independently be 0, 1, or 2, and
R201 to R206 may each independently be a phenyl group, a biphenyl group, a terphenyl group, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an indeno carbazolyl group, an indolocarbazolyl group, a benzofurocarbazolyl group, or a benzothienocarbazolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a biphenyl group, a terphenyl group, a phenyl group substituted with a C1-C10 alkyl group, a phenyl group substituted with —F, a pentalenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, an indacenyl group, an acenaphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a naphthacenyl group, a picenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), or any combination thereof,
wherein Q11 to Q13 and Q31 to Q33 may each independently be a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group.
In one or more embodiments, the hole transport region 3 may include a carbazole-containing amine-based compound.
In one or more embodiments, the hole transport region 3 may include a carbazole-containing amine-based compound and a carbazole-free amine-based compound.
The carbazole-containing amine-based compound may be, for example, a compound represented by Formula 201 including a carbazole group and further including at least one of a dibenzofuran group, a dibenzothiophene group, a fluorene group, a spiro-bifluorene group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, or any combination thereof.
The carbazole-free amine-based compound may be, for example, a compound represented by Formula 201 which does not include a carbazole group and which includes at least one of a dibenzofuran group, a dibenzothiophene group, a fluorene group, a spiro-bifluorene group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, or any combination thereof.
In one or more embodiments, the hole transport region 3 may include at least one compound represented by Formula 201, Formula 202, or a combination thereof.
In an embodiment, the hole transport region 3 may include at least one compound represented by Formulae 201-1, 202-1, 201-2, or any combination thereof but embodiments of the present disclosure are not limited thereto:
In Formulae 201-1, 202-1, and 201-2, L201 to L203, L205, xa1 to xa3, xa5, R201, and R202 may each be the same as described herein, and R211 to R213 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a phenyl group substituted with a C1-C10 alkyl group, a phenyl group substituted with —F, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a dimethylfluorenyl group, a diphenyl fluorenyl group, a triphenylenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, or a pyridinyl group.
For example, the hole transport region 3 may include at least one of Compounds HT1 to HT39, but embodiments of the present disclosure are not limited thereto:
In one or more embodiments, hole transport region 3 of the organic light-emitting device 10 may further include a p-dopant. When the hole transport region 3 further includes a p-dopant, the hole transport region 3 may have a matrix (for example, at least one of the compounds represented by Formulae 201 to 205) and a p-dopant included in the matrix. The p-dopant may be uniformly or non-uniformly doped in the hole transport region 3.
In an embodiment, the LUMO energy level of the p-dopant may be about −3.5 eV or less.
The p-dopant may include at least one of a quinone derivative, a metal oxide, a cyano group-containing compound, or any combination thereof, but embodiments of the present disclosure are not limited thereto.
In an embodiment, the p-dopant may include at least one of:
a quinone derivative, such as tetracyanoquinodimethane (TCNQ),2,3,5,6-tetrafluoro-7,7,8,8-tetracyanoquinodimethane (F4-TCNQ), and F6-TCNNQ;
a metal oxide, such as tungsten oxide or molybdenum oxide;
1,4,5,8,9,12-hexaazatriphenylene-hexacarbonitrile (HAT-CN);
a compound represented by Formula 221;
or any combination thereof,
but embodiments of the present disclosure are not limited thereto:
wherein, in Formula 221,
R221 to R223 may each independently be a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, wherein at least one R221 to R223 may have at least one cyano group, —F, —Cl, —Br, —I, a C1-C20 alkyl group substituted with —F, a C1-C20 alkyl group substituted with —C1, a C1-C20 alkyl group substituted with —Br, a C1-C20 alkyl group substituted with —I, or any combination thereof.
A thickness of the hole transport region 3 may be in a range of about 100 Å to about 10,000 Å, for example about 100 Å to about 5,000 Å. In addition, a thickness of the hole injection layer 31 among the layers constituting the hole transport region 3 is not particularly limited, but may be, for example, about 30 Å or more and about 1,000 Å or less. A thickness of the hole transport layer 32 is not particularly limited, but may be about 30 Å or more and about 1,000 Å or less. A thickness of the electron blocking layer 33 is not particularly limited, but may be about 10 Å or more and about 1,000 Å or less. In addition, a thickness of the hole buffer layer is not particularly limited as long as it exhibits the function of the hole buffer layer and does not interfere with the function as an organic light-emitting device. When the thicknesses of the hole transport region 3, the hole injection layer 31, the hole transport layer 32, and the electron blocking layer 33 are within these ranges, satisfactory hole transporting characteristics may be obtained without a substantial increase in driving voltage.
Although a film-forming method of the hole transport region 3 and each layer constituting the hole transport region 3 is not particularly limited, for example, a vacuum deposition method, a spin coating method, an LB method, an inkjet printing method, a laser printing method, a laser thermal transfer method, or the like may be used.
In the organic light-emitting device 10, the electron transport region 5 may be arranged between the emission layer 4 and the second electrode 5.
The electron transport region 5 may have a single-layered structure or a multi-layered structure.
For example, the electron transport region 5 may have an electron transport layer, an electron transport layer/electron injection layer structure, a buffer layer/electron transport layer structure, a hole blocking layer/electron transport layer structure, a buffer layer/electron transport layer/electron injection layer structure, or a hole blocking layer/electron transport layer/electron injection layer structure, but embodiments of the present disclosure are not limited thereto. The electron transport region 5 may further include an electron control layer.
The electron transport region 5 may include an electron-transporting material known in the art.
The electron transport region 5 (for example, a buffer layer, a hole blocking layer, an electron control layer, or an electron transport layer in the electron transport region) may include a metal-free compound containing at least one π electron-deficient nitrogen-containing cyclic group. The π electron-deficient nitrogen-containing cyclic group may be the same as described above.
In an embodiment, the electron transport region 5 may include a compound represented by Formula 601:
[Ar601]xe11-[(L601)xe1-R601]xe21
wherein, in Formula 601,
Ar601 and L601 may each independently be a substituted or unsubstituted C5-C60 carbocyclic group or a substituted or unsubstituted C1-C60 heterocyclic group,
xe11 may be 1, 2, or 3,
xe1 may be an integer from 0 to 5,
R601 may be a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —Si(Q601)(Q602)(Q603), —C(═O)(Q601), —S(═O)2(Q601), or —P(═O)(Q601)(Q602),
Q601 to Q603 may each independently be a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group, and
xe21 may be an integer from 1 to 5.
In an embodiment, at least one of Ar601(s) in the number of xe11, R601(s) in the number of xe21, or any combination thereof may include the π electron-deficient nitrogen-containing cyclic group.
In an embodiment, Ar601 and L601 in Formula 601 may each independently be a benzene group, a naphthalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, a dibenzofuran group, a dibenzothiophene group, a carbazole group, an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyrimidine group, a pyridazine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an isobenzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, or an azacarbazole group, each unsubstituted or substituted with at least one deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, —Si(Q31)(Q32)(Q33), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof, and
Q31 to Q33 may each independently be a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group.
When xe11 in Formula 601 is 2 or more, two or more of Ar601(s) may be linked to each other via a single bond.
In one or more embodiments, Ar601 in Formula 601 may be an anthracene group.
In one or more embodiments, the compound represented by Formula 601 may be represented by Formula 601-1:
wherein, in Formula 601-1,
X614 may be N or C(R614), X615 may be N or C(R615), X616 may be N or C(R616), and at least one of X614 to X616 may be N,
L611 to L613 may each independently be the same as described in connection with L601,
xe611 to xe613 may each independently be the same as described in connection with xe1,
R611 to R613 may each independently be the same as described in connection with R601, and
R614 to R616 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group.
In one or more embodiments, xe1 and xe611 to xe613 in Formulae 601 and 601-1 may each independently be 0, 1, or 2.
In one or more embodiments, R601 and R611 to R613 in Formulae 601 and 601-1 may each independently be: a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, or an azacarbazolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, a dibenzofluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a hexacenyl group, a pentacenyl group, a thiophenyl group, a furanyl group, a carbazolyl group, an indolyl group, an isoindolyl group, a benzofuranyl group, a benzothiophenyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, a dibenzosilolyl group, a pyridinyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a phthalazinyl group, a naphthyridinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a phenanthridinyl group, an acridinyl group, a phenanthrolinyl group, a phenazinyl group, a benzimidazolyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, or any combination thereof, or
—S(═O)2(Q601) or —P(═O)(Q601)(Q602), and
Q601 and Q602 may each be the same as described above.
The electron transport region 5 may include at least one of Compounds ET1 to ET36, but embodiments of the present disclosure are not limited thereto:
In one or more embodiments, the electron transport region 5 may include at least one of 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline (BCP), 4,7-diphenyl-1,10-phenanthroline (Bphen), Alq3, BAlq, 3-(biphenyl-4-yl)-5-(4-tert-butylphenyl)-4-phenyl-4H-1,2,4-triazole (TAZ), NTAZ, or any combination thereof:
The thicknesses of the buffer layer, the hole blocking layer, and the electron control layer may each independently be in a range of about 20 Å to about 1,000 Å, for example, about 30 Å to about 300 Å. When the thicknesses of the buffer layer, the hole blocking layer, and the electron control layer are within these ranges, excellent hole blocking characteristics or excellent electron control characteristics may be obtained without a substantial increase in driving voltage.
A thickness of the electron transport layer may be in a range of about 100 Å to about 1,000 Å, for example, about 150 Å to about 500 Å. When the thickness of the electron transport layer is within these ranges, satisfactory electron transporting characteristics may be obtained without a substantial increase in driving voltage.
The electron transport region 5 (for example, the electron transport layer in the electron transport region) may further include, in addition to the materials described above, a metal-containing material.
The metal-containing material may include at least one an alkali metal complex and an alkaline earth-metal complex. The alkali metal complex may include a metal ion a Li ion, a Na ion, a K ion, a Rb ion, and a Cs ion, and the alkaline earth-metal complex may include a metal ion a Be ion, a Mg ion, a Ca ion, a Sr ion, and a Ba ion. A ligand coordinated with the metal ion of the alkali metal complex or the alkaline earth-metal complex may be a hydroxy quinoline, a hydroxy isoquinoline, a hydroxy benzoquinoline, a hydroxy acridine, a hydroxy phenanthridine, a hydroxy phenyloxazole, a hydroxy phenylthiazole, a hydroxy diphenyloxadiazole, a hydroxy diphenylthiadiazole, a hydroxy phenylpyridine, a hydroxy phenylbenzimidazole, a hydroxy phenylbenzothiazole, a bipyridine, a phenanthroline, and a cyclopentadiene, but embodiments of the present disclosure are not limited thereto.
For example, the metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (lithium quinolate, LiQ) or ET-D2:
The electron transport region 5 may include an electron injection layer that facilitates the injection of electrons from the second electrode 6. The electron injection layer may directly contact the second electrode 6.
The electron injection layer may have i) a single-layered structure including a single layer including a single material, ii) a single-layered structure including a single layer including a plurality of different materials, or iii) a multi-layered structure having a plurality of layers including a plurality of different materials.
The electron injection layer may include an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal compound, an alkaline earth-metal compound, a rare earth metal compound, an alkali metal complex, an alkaline earth metal complex, a rare earth metal complex, or any combination thereof.
The alkali metal may be Li, Na, K, Rb, or Cs. In an embodiment, the alkali metal may be Li, Na, or Cs. In one or more embodiments, the alkali metal may be Li or Cs, but embodiments of the present disclosure are not limited thereto.
The alkaline earth metal may be Mg, Ca, Sr, or Ba.
The rare earth metal may be Sc, Y, Ce, Tb, Yb, or Gd.
The alkali metal compound, the alkaline earth-metal compound, and the rare earth metal compound may be oxides or halides (for example, fluorides, chlorides, bromides, or iodides) of the alkali metal, the alkaline earth-metal, and the rare earth metal.
The alkali metal compound may be an alkali metal oxide, such as Li2O, Cs2O, or K2O, or an alkali metal halide, such as LiF, NaF, CsF, KF, LiI, NaI, CsI, or KI. In an embodiment, the alkali metal compound may be LiF, Li2O, NaF, LiI, NaI, CsI, or KI, but embodiments of the present disclosure are not limited thereto.
The alkaline earth metal compound may be an alkaline earth metal oxide, such as BaO, SrO, CaO, BaxSr1-xO (0<x<1), or BaxCa1-xO (0<x<1). In an embodiment, the alkaline earth metal compound may be BaO, SrO, or CaO, but embodiments of the present disclosure are not limited thereto.
The rare earth metal compound may be YbF3, ScF3, ScO3, Y2O3, Ce2O3, GdF3, or TbF3. In an embodiment, the rare earth metal compound may be YbF3, ScF3, TbF3, Ybl3, SCl3, or TbI3, but embodiments of the present disclosure are not limited thereto.
The alkali metal complex, the alkaline earth-metal complex, and the rare earth metal complex may include an ion of an alkali metal, an alkaline earth-metal, or a rare earth metal as described above, and a ligand coordinated with a metal ion of the alkali metal complex, the alkaline earth-metal complex, or the rare earth metal complex may be hydroxy quinoline, hydroxy isoquinoline, hydroxy benzoquinoline, hydroxy acridine, hydroxy phenanthridine, hydroxy phenyloxazole, hydroxy phenylthiazole, hydroxy diphenyloxadiazole, hydroxy diphenylthiadiazole, hydroxy phenylpyridine, hydroxy phenylbenzimidazole, hydroxy phenylbenzothiazole, bipyridine, phenanthroline, or cyclopentadiene, but embodiments of the present disclosure are not limited thereto.
The electron injection layer may consist of an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal compound, an alkaline earth metal compound, a rare earth metal compound, an alkali metal complex, an alkaline earth metal complex, a rare earth metal complex, or any combination thereof, as described above. In one or more embodiments, the electron injection layer may further include an organic material. When the electron injection layer further includes an organic material, an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal compound, an alkaline earth metal compound, a rare earth metal compound, an alkali metal complex, an alkaline earth-metal complex, a rare earth metal complex, or any combination thereof may be homogeneously or non-homogeneously dispersed in a matrix including the organic material.
A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, for example, about 3 Å to about 90 Å. When the thickness of the electron injection layer is within these ranges, satisfactory electron injection characteristics may be obtained without a substantial increase in driving voltage.
The second electrode 6 may be arranged on the electron transport region 5. The second electrode 6 may be a cathode which is an electron injection electrode, and in this regard, a material for forming the second electrode 6 may be a metal, an alloy, an electrically conductive compound, or a combination thereof, each having a relatively low work function.
The second electrode 6 may include at least one lithium (Li), silver (Ag), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), magnesium-silver (Mg—Ag), ITO, IZO, or any combination thereof, but embodiments of the present disclosure are not limited thereto. The second electrode 6 may be a transmissive electrode, a semi-transmissive electrode, or a reflective electrode.
The second electrode 6 may have a single-layered structure having a single layer or a multi-layered structure including a plurality of layers.
A thickness of the second electrode 6 may be about 100 Å or more and about 10,000 Å or less, but is not limited thereto.
In addition, a sealing layer may be further arranged on the second electrode 6. The sealing layer is not particularly limited, and for example, may include α-NPD, NPB, TPD, m-MTDATA, Alq3, CuPc, N4, N4, N4′, N4′-tetra(phenyl-4-yl)biphenyl-4,4′-diamine (TPD15), 4,4′,4″-tri-9-carbazole triphenylamine (TCTA), N,N′-bis(naphthalene-1-yl), or any combination thereof.
Hereinbefore, the organic light-emitting device 10 has been described with reference to
The reorganization energy (ER) refers to the difference between the ground state energy [E(S0@S1)] (eV) of a compound having a stable structure in an excited singlet state (S1) and the ground state energy of a compound having a stable structure in a ground state (S0) [E(S0@S0)].
The adiabatic excited singlet state (S1) energy refers to the difference between the lowest excited singlet (S1) energy [E(S1@S1)] of a compound having a stable structure in an excited singlet state (S1) and the ground state (S0) energy [E(S0@S0)] of a compound having a stable structure in a ground state (S0).
The organic light-emitting device 10 may be included in various electronic apparatuses.
Such an electronic apparatus may further include a thin-film transistor in addition to the organic light-emitting device 10 as described above. The thin-film transistor may include a source electrode, a drain electrode, and an activation layer, wherein any one of the source electrode and the drain electrode may be electrically connected to any one of the first electrode 2 and the second electrode 6 of the organic light-emitting device 10.
The term “C1-C60 alkyl group” as used herein refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms, and examples thereof include a methyl group, an ethyl group, a propyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isoamyl group, and a hexyl group. The term “C1-C60 alkylene group” as used herein refers to a divalent group having the same structure as the C1-C60 alkyl group.
The term “C1-C60 alkoxy group” as used herein refers to a monovalent group represented by —OA101 (wherein A101 is the C1-C60 alkyl group), and examples thereof include a methoxy group, an ethoxy group, and an isopropyloxy group.
The term “C2-C60 alkenyl group” as used herein refers to a hydrocarbon group formed by substituting at least one carbon-carbon double bond in the middle or at the terminus of the C2-C60 alkyl group, and examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C2-C60 alkenylene group” as used herein refers to a divalent group having the same structure as the C2-C60 alkenyl group.
The term “C2-C60 alkynyl group” as used herein refers to a hydrocarbon group formed by substituting at least one carbon-carbon triple bond in the middle or at the terminus of the C2-C60 alkyl group, and examples thereof include an ethynyl group and a propynyl group. The term “C2-C60 alkynylene group” as used herein refers to a divalent group having the same structure as the C2-C60 alkynyl group.
The term “C3-C10 cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. The term “C3-C10 cycloalkylene group” as used herein refers to a divalent group having the same structure as the C3-C10 cycloalkyl group.
The term “C1-C10 heterocycloalkyl group” as used herein refers to a monovalent saturated monocyclic group having at least one heteroatom of N, O, P, Si, S, B, Se, Ge, or any combination thereof as a ring-forming atom and 1 to 10 carbon atoms, and non-limiting examples thereof include a tetrahydrofuranyl group and a tetrahydrothiophenyl group. The term “C1-C10 heterocycloalkylene group” as used herein refers to a divalent group having the same structure as the C1-C10 heterocycloalkyl group.
The term “C3-C10 cycloalkenyl group” as used herein refers to a monovalent monocyclic group that has 3 to 10 carbon atoms and at least one carbon-carbon double bond in the ring thereof and no aromaticity, and non-limiting examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C3-C10 cycloalkenylene group” as used herein refers to a divalent group having the same structure as the C3-C10 cycloalkenyl group.
The term “C1-C10 heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group that has at least one heteroatom N, O, P, Si, S, B, Se, Ge, or any combination thereof as a ring-forming atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in its ring. Examples of the C1-C10 heterocycloalkenyl group include a 2,3-dihydrofuranyl group and a 2,3-dihydrothiophenyl group. The term “C1-C10 heterocycloalkenylene group” as used herein refers to a divalent group having the same structure as the C1-C10 heterocycloalkenyl group.
The term “C6-C60 aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms, and the term “C6-C60 arylene group” as used herein refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. Examples of the C6-C60 aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C6-C60 aryl group and the C6-C60 arylene group each include two or more rings, the rings may be fused to each other.
The term “C1-C6 heteroaryl group” as used herein refers to a monovalent group having a heterocyclic aromatic system that has at least one heteroatom of N, O, P, Si, S, B, Se, Ge, or any combination thereof as a ring-forming atom, and 1 to 60 carbon atoms. The term “C1-C60 heteroarylene group” as used herein refers to a divalent group having a carbocyclic aromatic system that has at least one heteroatom of N, O, P, Si, S, B, Se, Ge, or any combination thereof as a ring-forming atom, and 1 to 60 carbon atoms. Examples of the C1-C60 heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C6-C60 heteroaryl group and the C6-C60 heteroarylene group each include two or more rings, the rings may be fused to each other.
The term “C6-C60 aryloxy group” as used herein indicates —OA102 (wherein A102 is the C6-C60 aryl group), and the term “C6-C60 arylthio group” as used herein indicates —SA103 (wherein A103 is the C6-C60 aryl group).
The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group in which two or more rings are condensed with each other, only carbon is used as a ring-forming atom (for example, the number of carbon atoms may be 8 to 60), and the whole molecule is a non-aromaticity group. An example of the monovalent non-aromatic condensed polycyclic group includes a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group” as used herein refers to a divalent group having the same structure as a monovalent non-aromatic condensed polycyclic group.
The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group having two or more rings condensed to each other, a heteroatom N, O, P, Si, and S, other than carbon atoms (for example, having 1 to 60 carbon atoms), as a ring-forming atom, and no aromaticity in its entire molecular structure. An example of the monovalent non-aromatic condensed heteropolycyclic group includes a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein refers to a divalent group having the same structure as a monovalent non-aromatic condensed heteropolycyclic group.
The term “C5-C30 carbocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, 5 to 30 carbon atoms only. The C5-C30 carbocyclic group may be a monocyclic group or a polycyclic group, and may be a monovalent, divalent, trivalent, tetravalent, pentavalent, or hexavalent group, depending on the formula structure.
The term “C1-C30 heterocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, at least one heteroatom N, O, Si, P, S, B, Se, Ge, or any combination thereof other than 1 to 30 carbon atoms. The C1-C30 heterocyclic group may be a monocyclic group or a polycyclic group, and may be a monovalent, divalent, trivalent, tetravalent, pentavalent, or hexavalent group, depending on the formula structure.
As used herein, the number of carbons in each group that is substituted (e.g., C1-C60) excludes the number of carbons in the substituent. For example, a C1-C60 alkyl group can be substituted with a C1-C60 alkyl group. The total number of carbons included in the C1-C60 alkyl group substituted with the C1-C60 alkyl group is not limited to 60 carbons. In addition, more than one C1-C60 alkyl substituent may be present on the C1-C60 alkyl group. This definition is not limited to the C1-C60 alkyl group and applies to all substituted groups that recite a carbon range.
At least one substituent of the substituted C5-C60 carbocyclic group, the substituted C1-C60 heterocyclic group, the substituted C1-C60 alkyl group, the substituted C2-C60 alkenyl group, the substituted C2-C60 alkynyl group, the substituted C1-C60 alkoxy group, the substituted C3-C10 cycloalkyl group, the substituted C1-C10 heterocycloalkyl group, the substituted C3-C10 cycloalkenyl group, the substituted C1-C10 heterocycloalkenyl group, the substituted C6-C60 aryl group, the substituted C6-C60 aryloxy group, the substituted C6-C60 arylthio group, the substituted C1-C60 heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be:
deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid or a salt thereof, a sulfonic acid or a salt thereof, a phosphoric acid or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group;
a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each substituted with at least one of deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid or a salt thereof, a sulfonic acid or a salt thereof, a phosphoric acid or a salt thereof, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q11)(Q12), —Si(Q13)(Q14)(Q15), —B(Q16)(Q17), —P(═O)(Q18)(Q19), or any combination thereof;
a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group;
a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one of deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid or a salt thereof, a sulfonic acid or a salt thereof, a phosphoric acid or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q21)(Q22), —Si(Q23)(Q24)(Q25), —B(Q26)(Q27), —P(═O)(Q28)(Q29), or any combination thereof; or
—N(Q31)(Q32), —Si(Q33)(Q34)(Q35), —B(Q36)(Q37), or —P(═O)(Q38)(Q39), and
Q1 to Q9, Q11 to Q19, Q21 to Q29, and Q31 to Q39 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid or a salt thereof, a sulfonic acid or a salt thereof, a phosphoric acid or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryl group substituted with at least one a C1-C60 alkyl group, and a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group.
The term “room temperature” as used herein refers to a temperature of about 25° C.
The terms “a biphenyl group, a terphenyl group, and a tetraphenyl group” as used herein respectively refer to monovalent groups in which two, three, or four phenyl groups which are linked together via a single bond.
The terms “a cyano-containing phenyl group, a cyano-containing biphenyl group, a cyano-containing terphenyl group, and a cyano-containing tetraphenyl group” as used herein respectively refer to a phenyl group, a biphenyl group, a terphenyl group, and a tetraphenyl group, each of which is substituted with at least one cyano group. In “a cyano-containing phenyl group, a cyano-containing biphenyl group, a cyano-containing terphenyl group, and a cyano-containing tetraphenyl group”, a cyano group may be substituted to any position of the corresponding group, and “the cyano-containing phenyl group, the cyano-containing biphenyl group, the cyano-containing terphenyl group, and the cyano-containing tetraphenyl group” may further include substituents other than a cyano group. For example, a phenyl group substituted with a cyano group and a phenyl group substituted with a cyano group and a methyl group may all belong to “a cyano-containing phenyl group”.
Hereinafter, a compound and an organic light-emitting device according to embodiments of the present disclosure are described in detail with reference to Synthesis Example and Examples. However, the present disclosure is not limited thereto. The wording “‘B’ was used instead of ‘A’” as used in describing Synthesis Examples means that an amount of ‘A’ used was identical to an amount of ‘B’ used, in terms of a molar equivalent.
Intermediate (1) was synthesized according to the synthesis methods described in paragraphs [96] to [105] in the patent application WO 2017/142310.
In a three-neck flask, Intermediate (1) (1.0 equiv.), resorcinol (0.5 equiv.), palladium acetate (Pd(OAc)3, 0.02 equiv.), (2-phenyl)di-tert-butylphosphine (JohnPhos, 0.04 equiv.), and tert-butoxy sodium (tBuONa, 2.0 equiv.) were stirred with a toluene solvent to react under an inert atmosphere at a temperature of 100° C. The reaction solution thus obtained was cooled to room temperature, and the filtrate obtained by celite filtration was concentrated. Then, the resultant product was purified by silica gel column chromatography, so as to obtain Intermediate (2).
In a three-neck flask, Intermediate (2) (1.0 equiv.) was stirred with an o-dichlorobenzene solvent under an inert atmosphere. Subsequently, boron triiodide (BI3, 4.0 equiv.) was added to the mixed solution and stirred again at a temperature of 180° C. to react. After completion of the reaction, an extraction process was performed thereon by using dichloromethane and water, and the organic layer thus obtained was distilled. The resultant product thus obtained was purified by column chromatography, so as to obtain Compound 2.
Intermediate (3) was synthesized according to the synthesis methods described in paragraphs [96] to [105] in the patent application WO2017/142310.
Intermediate (4) was synthesized and obtained in the same manner as in the synthesis of Intermediate (2), except that Intermediate (3) was used instead of Intermediate (1) and 1,3-benzenethiol was used instead of resorcinol.
Compound 14 was synthesized and obtained in the same manner as in the synthesis of Compound 2, except that Intermediate (4) was used instead of Intermediate (2).
In a reaction vessel, carbazole (1.0 equiv.), 4-bromo-2-fluorobenzene (1.0 equiv.), and a dimethyl sulfoxide solvent were added. Then, cesium carbonate (1.2 equiv.) was added to the mixed solution and stirred again at room temperature under a nitrogen atmosphere to react. After completion of the reaction, water was added to the resultant solution, and an extraction process was performed thereon by using chloroform. The organic layer thus obtained was then washed with water. The resultant organic layer was dried with magnesium sulfate, concentrated, and recrystallized with chloroform/hexane, so as to obtain A-1.
In a reaction vessel, A-1 (1.0 equiv.) and an ethanol solvent were added, and then, hydrochloric acid was added thereto to provide acidity. Next, tin chloride (II) (3.0 equiv.) was gradually added to the reaction mixture and stirred at a temperature of 70° C. to react. After completion of the reaction, the reaction solution was concentrated at room temperature under reduced pressure to obtain a residue. An aqueous sodium hydroxide solution was added to the residue to adjust the suspension, and stirred at room temperature to produce a solid. Subsequently, the solid thus obtained was removed by filtration, and the filtrate was diluted with toluene. An aqueous sodium hydroxide solution was added thereto to perform separation, and the resultant organic layer was dried with magnesium sulfate. Afterwards, the organic layer was concentrated and recrystallized with toluene/hexane, so as to obtain A-2.
In a reaction vessel, A-2 (1.0 equiv.), acetic acid, and concentrated sulfuric acid (volume ratio of 10:1, 4.5 equiv. of sulfuric acid) were added. Then, the reaction vessel was put in an ice water bath under a nitrogen atmosphere to cool the reaction solution to 10° C. Subsequently, sodium nitrite (1.02 equiv.) dissolved in water was added dropwise to the reaction solution for 15 minutes. Afterwards, the resultant solution was stirred at a temperature of 130° C. After completion of the reaction, the reaction solution was allowed to cool, and water was added thereto to precipitate a solid. The precipitated solid was removed by filtration, and the filtered solid was washed by suspending in methanol and filtering. Afterwards, the resultant solid was purified by silica gel column chromatography and recrystallized with chloroform/ethanol, so as to obtain Intermediate (5).
In a reaction vessel, 1,3-dibromo-2-chlorobenzene (1.0 equiv.), aniline (2.0 equiv.), and sodium-tert-butoxide (2.5 equiv.) were stirred with a xylene solvent.
Then, butyldichloro bis[di-tert-butyl (p-dimethyl aminophenyl)phosphino]palladium (II) (0.01 equiv.) was added to the mixture thus obtained, and the resultant mixture was stirred at a temperature of 140° C. under a nitrogen atmosphere to react. After completion of the reaction, the reaction solution was allowed to cool, and then, diluted with toluene and filtered through Celite to obtain the filtrate. The filtrate was concentrated and purified by column chromatography, so as to obtain Intermediate (6).
In a reaction vessel, Intermediate (6) (1.0 equiv.), Intermediate (5) (2.0 equiv.), and sodium-tert-butoxide (2.5 equiv.) were stirred with a xylene solvent. Then, butyldichlorobis[di-tert-butyl (p-dimethyl aminophenyl)phosphino]palladium (II) (0.01 equiv.) was added to the mixture thus obtained, and the resultant mixture was stirred at a temperature of 140° C. under a nitrogen atmosphere to react. After completion of the reaction, the reaction solution was allowed to cool, and then, diluted with toluene and filtered through Celite to obtain the filtrate. The filtrate was concentrated and purified by column chromatography, so as to obtain Intermediate (7).
In a reaction vessel, Intermediate (7) (1.0 equiv.) was stirred with a tert-butylbenzene solvent. Under a nitrogen atmosphere, a 1.6 M tert-butyl lithium pentane solution (1.2 equiv.) was added dropwise to the reaction solution at a temperature of −30° C. Subsequently, the reaction solution was stirred at a temperature of 60° C. for 2 hours, and boron tribromide (1.2 equiv.) refrigerated to a temperature of −30° C. was added thereto and stirred again at room temperature for 30 minutes. Afterwards, N,N-diisopropyl ethylamine (2.0 equiv.) refrigerated to a temperature of 0° C. was added to the reaction solution. Then, the reaction was stirred at a temperature of 120° C. and was allowed to cool to room temperature. Next, an aqueous sodium acetate solution and ethyl acetate were added to the reaction solution, and the organic layer was separated therefrom. The organic layer was concentrated and purified by column chromatography, so as to obtain Compound 97.
B-1 was obtained in the same manner as in the synthesis of A-1, except that 3,6-di-tert-butylcarbazole was used instead of carbazole as a starting raw material.
B-2 was obtained in the same manner as in the synthesis of A-2, except that B-1 was used instead of A-1 as a starting raw material.
Intermediate (8) was obtained in the same manner as in the synthesis of Intermediate (5), except that B-2 was used instead of A-2 as a starting raw material.
Intermediate (9) was obtained in the same manner as in the synthesis of Intermediate (7), except that Intermediate (8) was used instead of Intermediate (5) as a starting raw material.
Compound 100 was obtained in the same manner as in the synthesis of Compound 97, except that Intermediate (9) was used instead of Intermediate (7) as a starting raw material.
Intermediate (10) was obtained in the same manner as in the synthesis of Intermediate (6), except that 4-tert-butylamine was used instead of aniline as a starting raw material.
Intermediate (11) was obtained in the same manner as in the synthesis of Intermediate (7), except that Intermediate (10) was used instead of Intermediate (6) as a starting raw material.
Compound 101 was obtained in the same manner as in the synthesis of Compound 97, except that Intermediate (11) was used instead of Intermediate (7) as a starting raw material.
In the same manner as in the synthesis of Compound 97 of Synthesis Example 3, a process of first recrystallization, column chromatography, and second recrystallization was performed for separation and purification from Compound 97, so as to obtain Compound 201.
In the same manner as in the synthesis of Compound 100 of Synthesis Example 4, a process of first recrystallization, column chromatography, and second recrystallization was performed for separation and purification from Compound 100, so as to obtain Compound 202.
In the same manner as in the synthesis of Compound 101 of Synthesis Example 5, a process of first recrystallization, column chromatography, and second recrystallization was performed for separation and purification from Compound 101, so as to obtain Compound 203.
In a reaction vessel, 1,3-dichloro-2-iodobenzene (1.0 equiv.), o-anisidine (0.95 equiv.), sodium tert-butoxide (1.5 equiv.), 1,1′-bis(diphenylphosphino) ferrocene (0.05 equiv.), and palladium acetate (0.05 equiv.) were added and dissolved with toluene. The mixed solution was stirred at a temperature of 100° C. for 12 hours under a nitrogen atmosphere, and then filtered through Celite. Water was added to the filtrate to perform separation, and the organic layer thus obtained was concentrated. Afterwards, through purification by silica gel column chromatography, D-1 (yield: 40%) was obtained.
In a reaction vessel, D-1 (1.0 equiv.), palladium acetate (0.05 equiv.), tri-tert-butyl phosphonium tetrafluoroborate (0.1 equiv.), and potassium carbonate (2.0 equiv.) were added and dissolved with N,N-dimethylacetamide. The mixed solution was stirred for 6 hours under a nitrogen atmosphere, and then filtered through Celite. Then, water and ethyl acetate were added to the filtrate to perform separation, and the organic layer thus obtained was concentrated. Afterwards, through purification by silica gel column chromatography, D-2 (yield: 85%) was obtained.
In a reaction vessel, D-2 (1.0 equiv.), 1-tert-butyl-4-iodobenzene (2.0 equiv.), copper iodide (0.1 equiv.), trans-1,2-cyclohexanediamine (0.2 equiv.), and potassium triphosphate (2.0 equiv.) were added and dissolved with 1,4-dioxane. Water was added to the mixed solution to perform separation, and the organic layer thus obtained was concentrated. Afterwards, through purification by silica gel column chromatography, D-3 (yield: 80%) was obtained.
In a reaction vessel, D-3 (1.0 equiv.), palladium acetate (0.05 equiv.), tri-tert-butyl phosphonium tetrafluoroborate (0.1 equiv.), and potassium carbonate (2.0 equiv.) were added and dissolved with N,N-dimethylacetamide. The mixed solution was stirred for 6 hours under a nitrogen atmosphere, and then filtered through Celite. Then, water and ethyl acetate were added to the filtrate to perform separation, and the organic layer thus obtained was concentrated. Afterwards, through purification by silica gel column chromatography, D-4 (yield: 85%) was obtained.
In a reaction vessel, D-4 (1.0 equiv.) was added and dissolved with dichloromethane. The reaction vessel was put in an ice bath, and boron tribromide (2.0 equiv.) diluted with dichloromethane was added dropwise thereto. After returning the temperature of the reaction solution to room temperature, the reaction solution was stirred for 2 hours. 2N hydrochloric acid was added to the resultant reaction solution and stirred again for 30 minutes. Afterwards, the organic layer obtained by a separation process was obtained and concentrated, so as to obtain D-5 (yield: 85%).
In a reaction vessel, D-5 (1.0 equiv.), 1-bromo-2,6-difluorobenzene (0.45 equiv.), and potassium carbonate (2.0 equiv.) were added and dissolved with N-methyl pyrrolidone. Under a nitrogen atmosphere, the mixed solution was stirred at a temperature of 140° C. for 12 hours. After raising the temperature to 160° C., the reaction solution was stirred for 12 hours. After completion of the reaction, water was added to the resultant reaction solution, and the precipitated solid thus obtained was filtered. Then, through purification by silica gel chromatography, D-6 (yield: 85%) was obtained.
In a reaction vessel, D-6 (1.0 equiv.) and tert-butylbenzene were added and stirred. Under a nitrogen atmosphere, a 1.6 M tert-butyl lithium pentane solution (2.0 equiv.) was added dropwise to the reaction solution at a temperature of 0° C. After the resultant solution was stirred at a temperature of 60° C. for 2 hours, the low-boiling point components were distilled under reduced pressure. Boron tribromide (2.0 equiv.) cooled to temperature of −30° C. was added and the resultant solution was stirred at room temperature for 30 minutes. Then, after cooling to a temperature of 0 OC, N,N-diisopropyl ethylamine (2.0 equiv.) was added. Next, the resultant solution was heated and stirred at a temperature of 120 OC for 3 hours. Water and methanol were added thereto, and the precipitated solid was filtered. The filtrate was then separated and washed with tetrahydrofuran, so as to obtain Compound 301 (yield: 30%).
1H NMR and MS of the synthesized compounds are shown in Table 1 below. Here Compounds 2, 101, and 301 did not dissolve in a solution so that 1H NMR thereof could not be obtained. Synthesis methods for compounds other than the compounds shown in Table 1 may be easily recognized by those skilled in the technical field by referring to the synthesis paths and source materials described above.
1H NMR (CDCl3, 500 MHz)
(Calculation by Density Functional Theory (DFT))
The following calculations were performed according to the DFT for the following condensed cyclic compounds R1 to R3.
The ground state energy [E(S0@S1)] (eV) of the compound having a stable structure in a lowest excited singlet state and the ground state energy [E(S0@S0)] (eV) of the compound having a stable structure in a ground state were calculated, and the reorganization energy (ER) corresponding to the difference between the two energy values, that is, [E(S0@S1)]−[E(S0@S0)], was calculated.
In addition, the lowest excited singlet state energy [E(S1@S1)] of the compound having a stable structure in a lowest excited singlet state and the ground state energy [E(S0@S0)] of the compound having a stable structure in a ground were calculated, and the adiabatic lowest excited singlet state energy corresponding to the difference between the two energy values, that is, [E(S1@S1)]−[E(S0@S0)], was calculated.
Then, the fluorescence wavelength (nm) obtained by converting the adiabatic lowest excited singlet state energy (eV) into the light wavelength (nm) was calculated.
In addition, the oscillator strength (f) of the compound having a stable structure in a lowest excited singlet state was calculated.
Also, the highest occupied molecular orbital (HOMO) energy and the lowest unoccupied molecular orbital (LUMO) energy of the compound were calculated.
Here, the calculation by DFT was performed according to the following calculation methods (I), (II), and (III) using a calculation software, Gaussian 16 (Gaussian Inc.):
(I) S0 calculation method: structural optimization calculation by DFT using functional B3LYP basis function 6-31G (d, p) with toluene solvent effects (obtained by PCM);
(II) S1 calculation method: structural optimization calculation by time-dependent DFT (TDDFT) using functional B3LYP basis function 6-31G (d, p) with toluene solvent effects (obtained by PCM); and
(III) S0 calculation method: calculation of input structure by DFT using functional B3LYP basis function 6-31G (d, p) with toluene solvent effects (obtained by PCM).
In particular, calculation of each item was performed using the following calculation methods:
Ground state energy [E(S0@S0)] of compound having stable structure in ground state: see calculation method (1) above;
Lowest excited singlet state energy [E(S1@S1)] of compound having stable structure in first excited singlet state: see calculation method (II) above;
Ground state energy [E(S0@S1)] of compound having stable structure in first excited singlet state: see calculation methods (II) and (III) above;
Reorganization energy ([E(S0@S1)]− [E(S0@S0)]: see calculation methods (I), (II), and (III) above;
Adiabatic lowest excited singlet state energy ([E(S1@S1)]− [E(S0@S0)]: see calculation methods (I) and (II) above;
Fluorescence wavelength (nm): see calculation methods (I) and (II) above;
Oscillator strength (f) of compound having stable structure in first excited singlet state: see calculation method (II) above; and
HOMO and LUMO: see calculation method (1) above.
The calculated values according to the calculation methods above are shown in Table 9 below, and a qualitative description of the energy relationship is explained in
Measurements were carried out at room temperature with an excitation wavelength of 320 nm for each of 1×10−5 M (=mol/dm3, mol/L) toluene solutions of the condensed cyclic compounds R1 to R3 by using a spectrofluorophotometer F7000 manufactured by Hitachi High Technology. As a result, the fluorescence peak wavelength (nm) and the fluorescence spectrum width (FWHM) of photoluminescence (PL) were evaluated, and the evaluation results are shown in Table 2 below.
From Table 2, it was confirmed that the color of the fluorescence wavelength (nm) calculated by the DFT calculation corresponded to the peak wavelength experimentally measured. Therefore, it was accordingly confirmed that the color estimated by the DFT calculation was the same color as the actual color.
In this regard,
For Compounds 1 to 102, 201 to 203, 301 to 369, 401 to 413, and 501 to 532 that are the condensed cyclic compounds of the present disclosure, the DFT calculations were performed as described above. In addition, the same calculations were performed for Compounds C1 to C3 of Comparative Examples.
The results of the HOMO (eV), LUMO (eV), adiabatic lowest excited singlet state (S1) energy (eV), fluorescence wavelength (nm), oscillator strength (f), and reorganization energy (eV) calculated with respect to the compounds above are shown through Tables 3 to 9.
Here, as shown in Tables 3 to 9, the reorganization energy of the condensed cyclic compounds 1 to 102, 201 to 203, 301 to 369, 401 to 413, and 501 to 532 of the present disclosure was 0.100 eV or less, and was a value smaller than that of the known condensed cyclic compounds R1 to R3 in the art. Therefore, referring to
In addition, the reorganization energy of Compounds C1 to C5 of Comparative Examples was 0.114 eV or more, which is equal to or greater than that of the known condensed cyclic compounds R1 to R3 in the art. Referring to
In addition, as shown in Tables 3 to 9, the condensed cyclic compounds of the present disclosure had significantly reduced values of the reorganization energy (eV) compared to Compounds C1 to C5 of the Comparative Examples. Accordingly, it was confirmed that the condensed cyclic compounds of the present disclosure had significantly lower FWHM and significantly higher color purity compared to Compounds C1 to C5 of the Comparative Examples.
Therefore, it was confirmed that the condensed cyclic compounds of the present disclosure had a very narrow spectrum width and showed fluorescence with high color purity, particularly blue fluorescence with high color purity. It was also confirmed that the condensed cyclic compounds of the present disclosure had a sufficient magnitude of the oscillator strength (f), and the fluorescence efficiency thereof was also excellent.
The properties of the condensed cyclic compounds of the present disclosure were evaluated experimentally, and Compounds 100, 202, and 301 were used as exemplary compounds of the condensed cyclic compounds of the present disclosure.
For each of the 1×10−5 M (=mol/dm3, mol/L) toluene solutions of Compounds 100, 202, and 301 of the present disclosure, the measurement was performed with an excitation wavelength of 320 nm at room temperature by using a spectrofluorescence photometer F7000 manufactured by Hitachi High-Tech Science Company, and the fluorescence peak wavelength (nm) and the fluorescence spectrum width (full width at half maximum (FWHM) of the fluorescence spectrum peak) of PL were evaluated.
Here, the peak wavelength of fluorescence was not particularly limited, but it was preferable that it be within a blue emission region, particularly, within a range of about 440 nm to about 465. In addition, in the present evaluation, it was confirmed that the smaller FWHM of the fluorescence spectrum width corresponded with an improved color purity. These measurement results are shown in Table 10 below. In addition, Table 10 below also shows the results of the known condensed cyclic compounds R1 to R3 in the art measured in the same manner as described above.
Referring to Table 10, it was confirmed that the condensed cyclic compounds of the present disclosure, Compounds 100, 202, and 301, had smaller PL FWHMs compared to the known condensed cyclic compounds in the art, Compounds R1 to R3. That is, based on the results above, it was confirmed that the condensed cyclic compounds of the present disclosure had a very narrow spectrum width in PL fluorescence and exhibited blue fluorescence with high color purity.
An ITO glass substrate was cut into a size of 50 mm×50 mm×0.5 mm, sonicated in acetone, isopropyl alcohol, and distilled water in the order, each for 15 minutes, and then, washed by exposure to UV ozone for 30 minutes.
Thereafter, F6-TCNNQ was deposited on the ITO electrode to form a hole injection layer having a thickness of 10 nm, Compound HT1 was deposited on the hole injection layer to form a hole transport layer having a thickness of 126 nm, and Compound o-CBP was deposited on the hole transport layer to form an electron blocking layer having a thickness of 10 nm.
Compound o-CBP, Compound mCBP-2CN (host), and Compound 100 (dopant) were co-deposited on the electron blocking layer to form an emission layer having a thickness of 40 nm. Here, the mass ratio of Compound o-CBP and Compound mCBP-2CN was 60:40, and the concentration of Compound 100 was set to 1.5 weight % with respect to the total mass of Compound o-CBP, Compound mCBP-2CN, and Compound 100 (that is, the total mass of the emission layer).
After depositing Compound mCBP-2CN on the emission layer to form a hole blocking layer having a thickness of 10 nm, Compound ET17 and LiQ were co-deposited on the hole blocking layer in a weight ratio of 5:5 to form an electron transport layer having a thickness of 36 nm. Then, LiQ was deposited on the electron transport layer to form an electron injection layer having a thickness of 0.5 nm.
An Al electrode having a thickness of 80 nm was formed on the electron injection layer, thereby manufacturing a light-emitting device.
Afterwards, the light-emitting device manufactured in the above process was sealed using an ultraviolet curable resin (MORESCO, product name: WB90US) and a glass sealing tube dried in a glove box with a moisture concentration of 1 ppm or less and an oxygen concentration of 1 ppm or less in a nitrogen atmosphere, thereby completing the manufacture of an organic light-emitting device.
A light-emitting device was manufactured in the same manner as in Device Example 1, except that Compound 202 was used instead of Compound 100 in forming an emission layer. Then, the manufactured light-emitting device was sealed, thereby completing the manufacture of an organic light-emitting device.
A light-emitting device was manufactured and sealed in the same manner as in Device Example 1 to complete the manufacture of an organic light-emitting device, except that the emission layer was formed as follows.
Compound o-CBP and Compound mCBP-2CN (host), Compound Pt1 (sensitizer), and Compound 100 (dopant) were co-deposited on the electron blocking layer to form an emission layer having a thickness of 40 nm. Here, the mass ratio of Compound o-CBP, Compound mCBP-2CN, and Compound Pt1 was 60:40:10, and the concentration of Compound 100 was set to be 1.5 wt % with respect to the total mass of Compound o-CBP, Compound mCBP-2CN, Compound Pt1, and Compound 100 (i.e. , the total mass of the emission layer).
A light-emitting device was manufactured in the same manner as in Device Example 3, except that Compound 202 was used instead of Compound 100 in forming an emission layer. Then, the manufactured light-emitting device was sealed, thereby completing the manufacture of an organic light-emitting device.
A light-emitting device was manufactured in the same manner as in Device Example 1, except that Compound R1 was used instead of Compound 100 in forming an emission layer. Then, the manufactured light-emitting device was sealed, thereby completing the manufacture of an organic light-emitting device.
To evaluate the characteristics of the organic light-emitting devices manufactured according to Device Examples 1 to 4 and Comparative Device Example 1, brightness, external quantum efficiency, and device lifetime of the organic light-emitting device were measured. Light was emitted while changing the voltage of the organic light-emitting device using a direct current constant voltage power supply (source meter 2400 manufactured by KEITHLEY), and the brightness, emission spectrum, and the amount of light emitted were measured using a luminance measuring device (SR-3 manufactured by Topcon). Here, the external quantum efficiency was calculated from the amount of light emitted in the emission spectrum and the current value at the time of measurement.
LT95 shows the evaluation result of the device lifetime, and represents the time measured until the emission luminance, which decreases with the lapse of continuous operation time at a current value of 1,000 cd/m2, becomes 95% of the initial luminance. LT95 was expressed as a relative value with respect to LT95 [hr] of Comparative Example 1 being 1. The evaluation results for the characteristics of the organic light-emitting devices are shown in Table 11 below.
Referring to the results of Table 11, it was confirmed that the condensed cyclic compounds of the present disclosure, Compounds 100 and 202, exhibited blue fluorescence with a very narrow spectrum width and high color purity in the emission of the light-emitting device, and that Compounds 100 and 202 of the present disclosure had excellent external quantum efficiency and excellent device lifetime with excellent luminescence efficiency. In addition, it was confirmed that, compared to the devices of Device Examples 1 and 2 including the condensed cyclic compounds of the present disclosure only, the devices of Device Examples 3 and 4 including Compounds 100 and 202 which are the condensed cyclic compounds of the present disclosure together with Compound Pt1 which is a sensitizer showed the equivalent emission peak wavelength and the equivalent emission spectrum width (FWHM) to those of the devices of Device Examples 1 and 2 and exhibited the significantly improved external quantum efficiency and better LT95. Therefore, it was confirmed that, when the condensed cyclic compounds of the present disclosure and the sensitizer were used together, the luminescence efficiency and device lifespan of the organic light-emitting device were remarkably improved.
In addition, regarding the simulation evaluation results above, it was confirmed that the results were consistent with the tendency that the reorganization energy of the condensed cyclic compound of the present disclosure was smaller than the known condensed cyclic compounds R1 to R3 and that the FWHM of the condensed cyclic compound of the present disclosure was smaller than the known condensed cyclic compounds R1 to R3 (see
Accordingly, compared to the light-emitting device of Comparative Examples including Compounds C1 to C5 that are groups other than the condensed cyclic compound of the present disclosure, i.e., the group represented by Formula 2-1 or 2-2, the organic light-emitting device using the condensed cyclic compound of the present disclosure exhibited fluorescence having a narrow spectrum width and high color purity, in particular, blue fluorescence having high color purity.
In the above experiments, Compounds 100, 202, and 301 were used as exemplary embodiments of the condensed cyclic compound of the present disclosure. However, as represented by the above simulation evaluations, it is understood that other condensed cyclic compounds of the present disclosure also have similar properties. For this reason, other condensed cyclic compounds of the present disclosure and organic light-emitting devices using the same may also exhibit similar fluorescence emission with high color purity, particularly blue fluorescence emission with high color purity, and exhibit excellent luminous efficiency and excellent device lifetime.
According to the one or more embodiments, the inclusion of the condensed cyclic compound represented by Formula 1-1 or 1-2 provides high color purity.
It should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments. While one or more embodiments have been described with reference to the figures, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope as defined by the following claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2020-136804 | Aug 2020 | JP | national |
| 2021-055622 | Mar 2021 | JP | national |
| 10-2021-0089141 | Jul 2021 | KR | national |
